Department of Pharmaceuticals, Drugs (Prices Control) Order, 2013

4"" ^'o ̂ 0 'iMo-:i.3n04/99 REGD. NO. D. L.-33004/99 ■ f. I I 31RH slit S^he (Baxette of 3udia EXTRAORDINARY ’TFT II— 3— (ii)

PART II—Section 3—Sub-section (ii) yrfsignTwfm PUBLISHED BY AUTHORITY ■H. 1075] No. 1075] ^ f^crfr, 15, 2013/%n3-2S, 1935 NEW DELHI, WEDNESDAY, MAY 15, 2013A^AISAKHA 25, 1935 3lk v3^W TraRTO (3(httf?rtm) ^1^, 15^,2013 ‘IjT.3n.122l(3l).— ^IWR, 3il91tiic|7 ^ 3tf?rf^, 1955 (l955 ctn 10) ^[?r ETM 3 gRT ^rf^nfr cpt ft? (g?FRT f^m^) sn^, 1995 ^ gicfr ^ f^grg gR^ fg ^ 3lfllgRM ^ fW W t gr gR^ gg ggr t, 3T1^ gvRft t, 3isrfg : — ■gf&RT gm aJbf Rltn.—(1) 30^ gg gPT STtgftl (gftgg Pragu[) 3n^, 2013 t I

(2) tr ggfgg if HgjRH gif cTT^ git ^ I gftgrgnj.—(1) 3n^ if gig ggr ^ ̂ aFgag 3iirf$icT g ^,— (g>) "3ri?tf?tgg" % 3ITggggj g^ 3rf?ff^, 1955 (l955 gg lO) 3iMg t ; (^) itgfSrcB ^figeqj grufisi sftgfit" % sfrgf^ 3jk iRrm ^Hmift srfSrf^, 1940 (1940 gg 23) ^ 3itjtg RRRte giggif ^\3r^ gilt g^mgf^, ^ gt ggpil^ ggng siMg t sratg FIgg, 3)l^'Hlg't, 3ik cg-dgH ift t 3jk f^iggg g^frg gig if gr fMt if 'H'yecb ^ gig if giRg t ;

(g) "STS" ^ gig, gist, f%gn?g, jRffgi, sggR f^ gr ^ gift 3Fg f^r^mgr siMg t f^Rrir gg? gff 3ffgfSf g5f R5bOl3ft gff 3flgf^ ^ '{JPt'F gig if gBgRf gif glRft t;

(g) "3tfi|g5clg gffgg" ^ gilt g5fgg 3iMg t gft gRggg i| w 3n^ ^ ^ RPiRfcigl ^ f^ f^gg gif t; 1998 GI/2013

1.

2. (I) f, THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(u)]2 ^ ̂ 3lMtl t ̂ TTr-^)Sg>? ̂ aimlM cfj grji tji fUgjij m wi t 3ik sRpfe sifiraKrt ̂ t; (^) ^ ^ f^cR^i ̂ ̂ ̂ ̂ sif^ siMcT t aft? i?i^ atrptd 'g>rf aiftgKrf in fcpyft ̂ jcfgr^ cpt ^ 3it^fSrqt gjT ?srg> c^.f^ gft^ yerf^jysr ̂ t; (T^ "f^R ftPRfdT" ̂ I?I 3TT^ ?iwq^ J)cf,|^H ̂ cpt fltURTT f^lPmtdl 3lf?R!Tr t; (^) "R?iiq" ̂ jr^t t; (?f) "RPtPift" ̂ fcfRft g5t ■'d^Rdl ^ TfT \3?TC^ M ^r artdf^ TTT JRim ^ WT Tir ^ ^ ?cf7 ttt 3if?icp afp^Mr ^ f^rai^ ^ cjft afmfSr aifii^RT t ??Rf^ 3i?Rtd PiHfolf^d ^ t, aiSjtcT :—

(i) c^ afPrfgr 3icr>td (fuR# sirnfe ift t) ^ ij?pft (f^) s^mcft ^ ^ witI^ 3ik% ift t;

(ii) ■^'1«jl^l(^ H^nctt afmf^ ;

(iii) ^ cptf gfR[f?r 3ft? -mm ?iFnft sTf^rf^m, 1940 (1940 ^ 23) ^ wm ^ i ^ ; ' (oj) sfRflt tUI vflARcjj 'nMmx' ^ i|'Iyft<j ^ T[T fclRft ?lte f^PlRRi it 3raf^ ?ra^ ^ ̂ 1?ts[ftcT ^ fSif¥^ arf$i^ ., ■ , . . (c:) "?i?^' % ?T?^ 3TMd t; (^ "airam" ^ ??p^ sj|cb#ich ?!iqM aft? yRRttrr ?Ff|d ttrcI ?t?? %?fr ?8TFT ^ fllRft afipf?! cpi f?t^ c^ 1^ qT?d if eiHT afMrr t;

(5) "?yi4ld tp^" ■^r RPintcii ^ ̂ 3?{^ ail^tcpcrf tp gi?i TR?m f?p??t f!rf^ ^ 3Rft^ ?T?g>i? TJT yi'J'y yiwiy ^ t%?ft ?8TI%T p|cp|<j ^ ?i^ TR ?f^ (j^<ict5'< cjilHd if ddlK 'ZIT 3TPIRT Rl^) ^ ̂ TIT ddiJ^ui arMrl t; (S) ??T an^ MPiPT "f^P^Hldl" ^ ^ ̂^f^ t aft ^ 1^^ :iIT few ^ ̂ afk^if an ftRmW, amiTd tit fclwi ai?dT t;

(w) "dNK- am" ^ Riyfl afipf?! cfr ui^ vff^Rcp yoppR (jiRihh ctif^cp 3ti^ ^ snm? ti^ Tj^ 3ft? ^ -^if^ aft? PT^, TRW cn^ Ti^ epan? if fct^ g5t tj^ ■g?T afipf^ ?T)ft tp T^ 5m teR^ fct^ c^ ptm pp arjpid siRt^id t;

(d) ^ 3P^ c^ pritapfi c^ "^dcp? Rshcii Tpt Tpf^" ^ i^ecpy Rsltdl dfl ctflp^ pff pf^^icitp aifiptd t;

(si) "diap? apspRd arirp^' ^ ?rcpt? ^ ?RTi-?m tr ^^ Tpr aftpf?! % ?i^ ?cpRid aiRrapd tr fcppTi c^ 3iTcp% aiMd t;

(d) arfilchd'H yetpy c^tdd" ^ df aTfStcpcPT cplnd tp ^rgcp? c^tdd app ?aj|-[li( pr 3ft? '^edi, afr rpj aiPtfid t, Rrt P? aftpRi aiRiP wftppr dfr M arpnft aft? ai^ ^ ^ a? dfwi^ t;

(d) RtRft RRl^ PRI Tf "pRiph Plf^EP 3IT^' ^ PTRR if PRf PRT dp ?TRld RsPri TJfp 3lRptP t, ai?f a? d?I PRT TPI fctPRT iJeTI pftw appT t 3ft?Tjfeff a^ T^ PTft PRT T^ ddRIpft RtdRI pft ddirp -t; . (P) "?T^ 3IITI?TtcP 3itaf& ?PT?S2I 3ft? aRdR PlePTP PdlelP gRT ?1PTI-?TPTI a? 3mdP 3ft? 5p5tRid aft p^ aft? ?R!ad if arfERjapi pthip ^ aapRip ?rpp? ^ ̂ 3p^ aft asia ai^rjEtt if arf^iRid aft-p^ ?r^ 3pa?acp aftaRi Tjett, 2011 aiRptd t;

(a) i?i 3p^ c^ aTitPRff Rip "tt^ 3ftaf?t" ^ ?p^ spapapi aflaRi ?j^ if yj^ta^ ?na if RiRrf^ aft? pif^ aft aftpRi Rwpr RRrptdi gRi, pp aftaRi aft aftaRr ^ ?p8i fimiPR, pi% p^ TP apdi Pldl 3: airaiURni J •.' sfraf^r. ̂ ̂f ^ RRRw ̂irsfr crfk gr^ ̂ sfi^ ̂ ^ tit3t ̂ #fr JfTW 71^ j^PlWRl 3?f5litcr t; Cp) ^ f^f^Ri t 3irai sfh? wr 3fg^ ^ f; . (^) "pjnifeilpMfJra^' ̂ ̂ ̂5iiPiq> stM^t t ̂ aiN^r ̂ RiRirHi ^je^i ^ ̂ 3imfir Rif^rHi ̂ ^5^ t; (3?) "gSkci ^ ̂ 24 3jk 25 ̂r ^ arf^j^ t sft? s^nttr ^5tiT?r ̂ « t; (H) "^5eJK c^ cjW" ̂ 1^ 3ft^ ̂ M 3TM?r t ^ ̂ ^5c};7 ^ M ̂ t I^RT^r ^rf^rf^ 13fk ̂«iT%f ̂ ̂rf^ri^ ̂ ̂ f; (^) c^ira" ̂ ^ lk 5 c^ 3I#T M 3ft^ ̂ ̂ 4?t M 3ff^ t i

(w) "^5ci57 % Tn?g?r ̂ sfl^fM ̂ g>T ^ grar ̂ siggr^ siMct t ; (^) "3ij<jftd f^PiWRi" ̂ jm 31^^ ̂r 'HPif^d gjtf 3ft f^Ptfificr t ̂ ^ ̂ ̂ ^ ̂ f%f^ # ; (^) "31^^" 3n^ ̂ ̂ai t; (^itr) "afIcB f^^' ̂ fct># fcl^, 31'WdM, afWgTOT, fxif^ddi, ftrsn ̂ m f^ 3F?i 3?firaj^ ̂ sfmfM ̂ f^gj^i H’n c[5t^ cijci^ifl ̂ aff^ra^rf ̂ it t; ' ' (■?T^ "aitcij f^gni ^q;^' ^ ^ 3ik jfRfIr I^itft, ^TRcf ^iwr ^ wi-wj w ^jair iftf^ ̂ w^sft m aftg> fcm>^r ^fj^r 11.

(2) 5T^ 3ik ^ Tpr 3rfSlf?raiT ^ 3imfSr 3fr? 5RmR WnSt srfSingJT, 1940 (1940 45T 23) ^ uRnif^d ^ 3PI ^ 3ik cfjT ^ 3Taf ^ ^ ^cfvf 3TfSrf%^Ryr t 1 <it<dchi ^n afl^fitqf flftPffM cjt f^mtdisff gjt ftt?i.—^iWR—3. ^ -m aY45%cr if ciiRi^tcR .wfm gft ^ ̂f(i) 3TFTra^>ra’ ^ ̂ ̂f ^ sitwf^nif gft iraf^ vsqeisraT ;fM afk f?rd^ ^ RR^Rd cp^ cfft ^ ̂ f^t?^ 3ft W4> UT 3jt^ TX\ RPiPfRi ^ 1%^ ra PlHfdl 4ft ^ ̂ frf^ W4) 4T JI^ 3Tl4f^ 44 wn44 4ST^ '4ft, 48nf^j1%,f 4ft ^ 3F4 fc|PiRcii3Tt 4>t «r4^ ^fWTSft, 3R4cn^ 4T 3ff%^ 4ft ^ ̂ feT? RPififRl 44T% 4Tefr 4ft 1%^ ^ ̂ ^ ;

(ii) ^4% (1) ^ 3fEft4 ^ 44t4r4 ^ ^#>4 3^qRjict5 'dkjectff 4T 4^4 aft^f^ 4T RR(4f[?i4Y ^ RRataiaft ^ ^ ̂ am 4^, 4fr 4? sm^ RRafm, ^ wi ^ 3ft44i 4ft ^14444 Rdd 45^, 3T^f^I4 ^J44T ^41 I fiti^ RRWQt 4jt 3rf?t44m 4ftim c^t -hmurt. —(i) RRR'c 4if^ afk w 4?t 3m ^ 44TRRf^ ^ ^ = 4434 1. 4444:, ^54454 Rs^ ^ RRRIcf 3f4t4 ^ft (w) ^ft 3ftw 4ft44 45t WHT R**iRi[^d 3EW if 45t 4nT33ft : . 544i4 4ft 3ihra 4>t44, 35t(T?4) = (44 3it4fSr 4^414 4Tf^ 34|xT ^ 34414 44 41444 ‘ 34f4 ^ 443 uRijld ■^l 31R43 41 44144 41444 3141 41^ 31t4f^ 4T3ft 41^ 3ft43YffR43 4i4td% 44 ^4434 45t 4Wr ^ 4t4) / (^ 3M& ^ ilRm 4lf^ 34^ ^ 34E44 44 ^ 41444 34^ ^ 443 4f!ltRl ^ 31^43 41 441^ 44144 4T444 3141 41cft 3114^ ^ ^ 4i^ 3ft4 3^^ 4n4icrfl 45t ^ 44154 I )

4. 4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]

2.- 3raI^cI ^ 3ri?icpfiTT ^ ̂fjwrr Rnl^Rdd ̂ : it(^) = Tjt(xFFr). (1 + TiTr/i 00);.^ tr = -gm ̂ 1 ^ 3tWir ^ ?if^ atk w ̂ ^ ajk^r * O<■ ^ ̂ JTTf^ ^PT JlfcRRT 3jk ^ = 16

(2) ^ ikl (1) ^ 31^ >EPTlk?T 3lk WPTY gM 3lf?Rjfl|?r 3?1?raiTPT cfW 3R^ aTPHf^ ^ ̂ I ^lk5WT^#T3iTc^^3Tl^g5t3JSg5Yg5kHg5tWTT%4^ gTT^(l)^r^!iaim^M I

(2) (i) gRT Tk^ 4Nk ^r ai^qHSI ^ 3fkf^ c^ ^ 15 3ItfH ^rf f!kn?^ cff[ ^RmJt ^!Tf?rfcr ^ kfipiRijil Xf^ ^ 3f[^ ^ ^ w krro gn unipft i

(ii)W=i£« « ?f^ra .K (i) « Jjif, fiEta liS ^rntyR t%^RT ^ umr^ I

6. ^ cj^ CRI^ ^ ^ ̂ ̂ ̂ ^ RY. -kl 4 % (1) it ^ c^ g^tRrr cPT RIM,— ^) ^ g5M5? 1^ cf^r gflM ^ ^ it gn 3tkRi gW ^ Mtt ^ m;3rk

5. -(1)aig^qfxRT RPiRfd,^ 5jrig7'< tt^nr'cpt 3itMaTTEIR RY N Rl^ gr 3Tf?fcp giRMsm wt g]k mm c^ fkR Rig rngfcTTatt ^ gt 3lf?tgHTR gJtgg gft ^TRlgRT kpgfkfeg g)R if g^t gnRjft : R»R krkRtcIT ^ )pc<^'< Tqj^dl W ^rjT'eid ^*lci ^ ’d^iuidl PiHf^Rdd ^ ̂ nijf) ;. ^1 : RgRg:, ^ 31^^ mm 3rgtg -Tft(Rg) gn tlf^ g^t ajk^r g^t^ gst ■giR R g5t RIKpft ; 'ftwn kiHf^fed = Rl^KitSk gtlHd grkt 3<3vijrgd gtt 'gjggR gfr gttgg 2 ̂ 3fhM R^M g^ kWfT ^ fkR kt Rt 3lteT - ̂gm^IRfkR)g5t^5gg?RfMRTg^3tkRT^^g^^grrRf%iRn ;?R=3t^ gttkMT i ■ 3T^ f!rf%f5tf^ ^ ^(^) =^(RR).(1+IJR/ioo), gl?f TR ■ ^(RR) = ?Rif RiRR gRur 1 if RR = ^JggR f^sfjcll gjf dlRtid gR RfitgRT afk ) /rr*ioo) }gi?f. 'J>T ggr gRfSig srg^jkfg RPiRfd gff ^iggiTR Raf^i git afkm gttRg. 3jk gRTgR ’Jcg = 16 gRR 2 s ■ M OT ^ JiljqflKI 3,,, ^ 3(1,, ^ ^ ̂ ̂ 511-73^ 3(ii)] ITO ̂ WTS : T7IHT PlHf^Rad WT Tf: WTd; 3T8jfe ^f('^) 4?'^'^’'! ^'I'dd 0ldd ̂ ̂# rRUr 1 ,) /tj^*ioo) }^,7ft(TJ^) =^,u,{l-('fti1+^i2+ 7f[^ = ra pififfir ^ ^ 3iW ^ ^ ̂ arflTcp^ ^ RiPiRfrI ̂ 0lHd I « tft i= Pts^ ̂ afPfcT cfSpM ̂ ̂HWn ̂ Pr. ̂ ̂ 3#WT cf5WcT 711^ RRRra ̂ w 4 ftxfRpfPr srjqto RRPiPr ̂ wr €t ̂ ̂ RiRhc^n ^r 3?^^ (^r 4 c^ 'OT (l) "5^ 1 ̂ '^®TT 'd'lPm) ^ccf)4 fc|5f)dl cf^r sipid cfpTO 4)41 cPT wfd^ld I f^^iratSpT RP[4Pr wr ̂ ̂ ̂ Rif4)^r w4 4 ̂ 3t^ PrPffifM ̂ wn I • trui 2. cT?q?ErRT PtPtf4fcr aiafe P(c) ̂ atPicf)^ ^Ptrt^ 47#ri ̂[4 ̂ im^41 : P(c)=P(s)*(l+M/100),^ P(S)= vJ44VcRT WJT 1 4 l\/l= ^e'ct?? oOTqPl ̂ emr #fiT c[)T % 75^ = ^^cbvpTi- TiTfT Pmm#T 31^^ f4f4f4Pr, ^ 5^4 4 3i14cp 4 3t4Pi sn ̂ t ̂ 3t^^ ptf4f4Pr 4 Tj)^-wn4 7f4 3tW ̂ ^4t 44 tjtt PiPIk^ jra4t 4 3?4Pt 3ri 31^ f?iPrf41M 4 ̂ sjTTn4 4t 34to 44i^ 4 44?TcRtt 4t ̂ f?mR ̂ 4 TRwm 444^1 4t ^ Pfiot 3itoT 4Prt, 14fi44 144^ 4 344^1 4Pt?t 4\ 4wn 4 Pf ;

(iii) 44 arjqJ^ PrPrf4Pr 4 3F? 44r4 ̂ ̂pra) f, 3rjfj4 4 7# f sfp PTEfRitPr 3rj{^ ^qPif4dm w4 44 14 siP^kF 44^ 444d 4t ̂smpft : : 44 3T^^ f444f4 3t4cT P(s) 4t ̂ )^ ̂1^4 4t 7i?4 3fPicT 44cT PiMi^'dR 4-iPid 41 v)ii^4 : FT = PtPttt 3rjqf4T PrPrt4PT 4 wn4 4r 3fPF 4Pi?r 3fk 16 tRDI 1 P(s)=Pm{l-{Pii+Pi2+...)/N*100)}F4. Pi4%t PtPTf4Pr 41 44tt, Prar^fPr PiPrPrPr 4 ^JTnTT4 4l 3fpTcT 44?f 4-iPidPn,= 4PTcT 4 fcTTj 41 1 ^ ■ PpTHCTqwF4 4l3flw4lFT444TTF4r4PF4l7Tf 73Wcm4lFTPraP:77Tl4«4 44j4f4F^ 3T^^ PrPrl4Pr 4 5t^ ̂4, Pi1444 Tra4 4 sft 3t^ 14Pt14Pr (4:1 4 4 (1), 1 4 7i?jt -tjqPid) 4 jdcf)? oi)im4 4l sfpRT 4PtcT 4 % 41 f41 N= P(xn^ 3T^ 1444P 4 3T^ 7341144^ wl 4 44 31^ 14^^ FW 2. cRTTFira. 31^^ PPrm 3T5jPt P(c) 41 stPrkPT 41ft P-ii^i'diy tfiPrt 41 ftf4 : P(c)=P(s). {1+M/100),75T?1 P{s)= 73q4FT tRiq 1 4 444h 1477 Trq 31^ 3T^^ f444P 41 ^ 3^ l\/I= ̂ )2^f)^ 41 ̂ 4Ptt FI % 3fp 7J^ = 16 ^^4 FT7TT4 41 3ft^ 41ft ̂ 44 T^q 144t^ w4 4 ̂ ̂ SXp 4 44FTF 41 f41 7R Pmr^ f4i 4 TTFTm 444h 41 fMI ^ ̂ Ptt^ 3ftFT 417F PffSPt 3T^ 144f4P 4 3Tf4WT 4^ _ PtFT 417Tf 13fp (3444 41ft. PrqFiT)1 . r 21 FfT % 4 3414^ 1441 FcT 4 44 Itj 41, 73^1 41ft ttrfk ^ ̂ 1995 4 34PT STPRjPRT 4l7T^t^73iT4?T(l)^^^^^' THE GAZETTE OF INDIA : EXTRAORDINARY [PART 11—Sec. 3(ii)1 • <’> ^ ̂ art!^ arttefM ^ 3jk J1T%I cF5t. ̂ ̂ ̂ 0^ OTm? .W'f^^aff gm f?IW ^̂ 3tfi>g>H^^ecJiYcfltTRT=3Tfi^

(2) J ^ 3?t?mKPT gJScfJ? cf^TRl ̂ IRcPR gRT 3mr% gi^cfR 3fl^ ;fajp^'Tf raPlHldT3Tf gm f^iHI^'HK j%TRf gfRjft ; cTPJ 3TrerR' 1^! arffenr ̂ egR gSt^m = ̂egR g^im + wp[k gR, gfj te ->7 amrt^ te„7 a, ̂ TTTrt t at w aqte 7rt« gR,« 3rtaJte ™,,Sr ̂ ^ ̂ ^ 3fKfM ̂ ̂ gMR 3TTmf^ 3^ ̂ ^ gn 3}k 3ng5% gg ̂fnigR 7TT ̂ JIM gR^ ̂ ̂ET ̂ 'fraBw ̂ Jira gR^ c^ f?tRft 3Hf TR^ w 3Tf^ ̂ I r ̂ ̂ ~^^ ̂

(4) gTRR ̂r ;3gRST ̂ 3TtgfERff c^ ̂ jggR g5^ ̂ ^ Hggg c^ amlgg g?t grf^r c^ ̂ .^.77777 TTrf ^ 3nEn% 3Tig5;5r, ̂ 3ff^ ̂ ̂ ̂ r;- r: -- ■31"^, 2012 gg, 3ik 3rfgRTflRf gJt g# f amr ^ ̂TT^ ^ ̂ ̂W^g5^g^^1^°i2^3^ggT^ ? ̂ ̂ 3T^^f?lf5rf^gngng?frgggg75[5TRgR;Hc^^HH7^ ^ ^ ̂ 3T^ 1^ Smi5, Si ?^31*'5’2^’ **** ^ ^ ®'^f^f^) 3TT^, 1995, 3,£j^ ^,7^ ^ 3^. ^ 3rf?Rj[^ gft f aftgl?! (gatgcf ate»® « ate at* ftro OT lilftit teirtt »=» ate ftftefa ^ ̂ » fitefflteS an atfl*, atetef * *, If; ̂ * T* (^ atftajjte « #. airt aai art aigfe 30 wt anaa ^ '■’^^ ^^70 ̂ ^a* te ^ WateititaSaifin^aaiaaafiiaaaiaaaa^teteaTOrttinrXf ^ '^' « " r*" ”11. artteEin aSaa ai Dai aS mjaa aflaa _(,i teiate,.,*,*, ^ at, ata a* gaaa (ate ta^ ^ ̂ ̂ ^ (g5tgg f^rggR) 3n^, ggi . - [WI-II-131IS 3(ii)] 7lira ̂ TTTO : smiwi ^ M 3jk ^ ^ffrRf ̂ ciffriH, ̂ -qanl^, ■ WgIT IIT W^ ̂ ̂ ̂ ̂ ̂ WTT^ I

(2) 31^^ if ̂ RiPiffil^ ̂ 7|w ̂ cfn ̂ Tf, 3fmf^ 3!k ;RTm ̂fTFnfr 3rf?li%JnT, 1940 (1940 ̂ 23) Sik 3T^ sRT^J ̂ kflRt "JI^TT RPlR'^C 3fp^f& c^ ̂ TTcpf PlHcl^ 3ncf)R ^ 3)j'(^Rid RiPiRfci ̂ uajif^iflr, arf^rcpcw cf^kRT ̂ ^ ttwit ̂ c^ ̂ ̂r villi'•'FT sfk-'ki 5 ̂ ̂ ̂dctivi gfTRcT ;FRr Wr ̂ fk<? sri^ % afr^f^ ̂ ;rtcr ^ wn ̂ wr ̂ ̂ ̂ I

12. (^Pl4dl 5RT 3fR3T ti^ 31|cl!<^ch WkfM cJi) ^ ̂i Rf^Wfcl^if ^n v^ARcj, 'ttni^x) c^) c^^ira- (i) 3rjqf%H [^PiP)Rf ̂ arm ̂ f^Pinldi wfiR ̂ ̂ ^ Rdd cfi) 7|^ aif&wfT ̂ fikcT ̂ 3r5?jf^ RPiRId cf5t cfikH Piw feP? ̂ <Rra ?kT I

(2) 1?tRff SRT rapinldl ̂ fcRPIPT site ̂ 3frW WT t cj?T ̂ 13 ̂ ̂ET c^F], I f?kniH QPlHi^aft c^ fktj 3i^<jRra f^Pi(Jfrd<ii eit) ci5kRT- (i) ^^reiiR ̂ f?T wr kRRf q^t 3jk aifiRjfeT ̂ srflrcfKFT cfikcT (eft W^IeT gR, kt elF; ^ 3#^ c[5kcT eR 3rjqJ^ ftMM iftts EJT FTEtkEf) EIT ̂ vhMld'it cFT ^ 3lj'tirtld RPiRfM E^ RlR^rfdl, 3rf^|EFdF ̂ itFcf (EFT TfarFftEI cfR Tiff FTFJ #) 3FTf?lEF Rift -kft RPlffiRiq't cfft cfftFR ̂ STEftgrft Efkft : ERg fftftftr 3T^T3l^ En srftor ̂ ̂ 3t%eftt cfft c^Fftn eft ijft ef^R ft ret^ 3?^#^ f^RWRiftr eft FFTk ft, fftfftEftdT ftrft 3Tf?RJ^ ^ dlftEJ eft ftdTFftR fftF gft 3fEt^ ̂ ftftR ETg- RiftkftcT efikn ffti ftEftF 3T^T3j^ fftfftfftfft ̂ wtoF ̂TSefR ftftTFI 3rf?fWT-^ftERr (EFT WfttET EfR, Fft RFJ, ̂ ) Eft 3Tf?mT F # I

(2) ̂ EIT fttftjfteF RT 3T^Tjf^ rafftIftfftEft ^ fttftf EfRTERf Efft fttf Ejft ST^qt^ 1ft1ftfftf!rEft ^ Efflft fftOTFT fftkpftdT, EfTRfiR lRT‘|R TfefTRlftEm 3k3Tf6RjklR 3Tl?Te^ (EFT EfSJTEftEI efR Rt RF; #) Eft efftlFT TR feRJFFT STEFft 3^?!?^^ ̂ RefR cfftTfR wft Rftft 1 ' ■ ̂_

(3) ftR 16 ̂ REjftR (2) 3ik EJEfftR (3) ̂ EJEfftftf eft STJRR, ijft Efft ̂ W ̂ EfftifR EfJREfi ft ^ 3T^RR 3rfftRdF ̂ RefR cftkFT ft grfftcF Wraft ̂ RT EfTRcft t : ER^ sfteF cfftFcT ^TJ^TEfT ft fftR^ ̂ ̂ ft, ftR 16 ̂ REf ftR (4) eft ESEtM eft ar^RR eftidd ft 'RRRFft

13. epft efft RFFft I

14. 3rj#R fftfftfftfitElf Eftt arfIjEBRR Eftkra EJH fftEIRR ^ (1) EfFaTR, EIRTf^, % 4 3ik ftR 6 ̂ EJElftftT Eft :, 3FR}feT RllftfftRTEft ̂ STfeFTR ̂ fftEFT afk 371^^ Rftftt 3fk efftf fftfftEftdT R^ IRT ̂ iftRR ̂ R^ 3fk 3TlftR}i^ 3TfSRFTR ̂ (RR EfSRftjR gR Rt RFJ, ̂ ) Eft R^IcR EfftRR eR 31^1^ (ft Pi 1ft fcl ft) Rft R^ ftftRT I -

(2) RTBT Efftt EfRRTR ̂ IftlftR^RT (ftEFT ̂ et^ sik 3fpR3l^.3ltftranTR EfftRR (eR EfRFftEI R? Efft ft t RFJ ̂ ) Eft 3fPfR E3Rra7 RftRR er (ftlftlftPr Rft ftRR t EffT ftRT fftPlRtR-3TfSlR^ 3FTT^ ftEft arfftEp MR Rft RT^ ̂ E3Fn gRft cfiT RTEfl ̂ I lisT^^ f^f^^f5^fM Eft IftaRTR fftfftRhnaft Eft fftiET 3ftEifii

(1) RWR "EtiWleftl^eftlftlPleRT" Eft (^■^(dl ER 3ftRf?lEff R?t ycep\ cfilddl Rft (^miR^.I RRft ^ anftR ^ SlPFqRRT ^ RTR IftR ^ ftiRR ^ ̂ ̂ ^ ̂ ̂ ̂ . (7^ RSt STTERElefi afraPlEft Rft R^ ̂ ft ERTTfftPrt^ 3» RR Efft^ f^TH fftPFftcTT E|RRT 3fk R^T REft3»RR3nRTEfRdTt, Ef^ft^ f?l™ ^^^^TT^R Rft 3T^ 2 ^ 3fEftR fftPlf^ TFOT 1 ft Eft ft# R^ 3ftEft?r Rft EfftTRI Eft Ejft R^ftRR ft ? (kEf SnftRR RkRT 1

(3) ret ftR (2) # 3I#R 3TTftRR Rft Jnf^ er ^TviTR tf REIRSI Rf sftRflf # ̂ ̂ ^ ftR (1) ^ REk# ^ 3f^ IftEFT Rkftt 3jk RTRR ft ST^etR^ rI 3fmf^ R5t RRT ft.R^ Eift 3TftfftR Rkftt # "EfJTRk^TFftfftEfR" ftT kt^ er anft^ # RTW rM stk 3T^RR, TlRjR RitRR ftR 5 # RET Rft fftftiR# Rft e{8TT# EfTfftIftr , . ^ . .. „ ,anftRR Efft TTTf^ # #R fftR ^ ftkR RWR Rft Rf 3ftE^ # ̂ RR5R EftkR eftt TReTRRR RkRT 1 8 THE GAZETTE OF INDIA : EXTRAORDINARY. [PART II—SEC. 3(ii)]

(4) ^ ̂ (3) 3T#T ^ Rlf^ tIY ^ 3ihf& ̂ #?T #fK' 3ik M M ̂ 3H^ ̂ H 3n^ cf^r HPj ̂ I

(5) ̂ 3rjg|^ ^ teiH 1 ^r ̂ sihf^ cf5t cfftrT^i ar^H'icjH ̂ an^l^ Wr ^r 3WW WT t ̂ ̂ fcrfM^r tiWK INI 3ik aif^Rjf^ ̂ ci?Ntt ̂ arf^ra? ^ ̂rrf^ 3l1%f^ SIM yRT ̂ ̂ ̂ ̂ I

(6) 3rjq[lRT [^iPiRlci ̂ %nTH f^rPiHldi ^mcim irt ^ ci?[tri (ept Rsnik cr ̂ ̂ ^ ̂I^RR ci5[tm M M ̂ 3iW^ cffr ̂ sk ̂ f?rfMdT ̂ ̂ ^r ̂ ̂JIWN IRT ^ ̂ ̂isg?7 cfW (eft w=ftTi cM ̂ ̂ ̂) ̂ i3raicR t|?[Trci M af!^ gir ̂ trit ttmt ̂ sirtt t ttI ̂ aft^ csj ̂ RPinldi aite Tmrftd w^r ̂ ^ arflrf^ aif?M Ji^uRd ^^ di^ ̂ ̂ cp^ dd dFft ̂ I

16. 3I^^j[%d C^ arfijcPdTI clJtnd cBT gd<[«ni -- (l) ^ 1 arfe gfr m TJ^, gif ̂ cnf^ aflcp cffiw (;g^ an^ c^ arjuN aij^Rid RPiffifci^l arUtcpcR ciJtdd dit cfiMl aik,d^ cf5t i aii^di aif^t^|tid giMl I

(2) ^,anEMMd^^aii[dfdM^rTT^ ¥R3T^T3l^idf?rf%WM cf5t sifeRPT fddJY dfldd (TPT 3IR it) d^r afk ?Ri ̂ 4 RNdM cpT ditt Tji argjfldd 3lif$Id d^ #dT i

(3) ^ di^^r dddEPiit d5t diEft t Tfr gditOT ̂ id? dtt aicrf^i c^ itcNddw - 2'^r di dt ^<?lq^|p|0 dl dNdftdJ ̂ if RNdJR d^T aiTifid %dT dlppiT aiW dd id c^ ai^d Wdddit d 1^ did! dd sitedd gidcM didd (dd aiN it) ̂ 5dftdM d fiid uni ^ did ^r aiat Bdidi afk dd^ f^Rdldi ̂ gdifer -^ticPdd ̂ iddJR didd (dd aiR it) ̂ ailid) dlf^ Wd di aiUM diid ̂ di diin ̂ dtid ufdl dTdi ̂ diit ̂ I W ̂ ^^t d?n i, aifidRid jddJR dttdd i .ddfeiiit dntt M afk fifid ai^^ dT' dMiY i ddcTST fikrtM ̂ didi i gdifei atfididd didd di aifid^ dft drirf i iji fiftdtdi M aifgRjddT di diife c^ 45 fid ci 3idfi c^ itdd d? ̂fiRdd dki f?d i# ai^^jkid fifififi di aiflicpdd ^ddid df^ (dd aiR it) gdif^d aifidHid dftdd (dd witd ̂ kr did]; #) ̂ ai1?M d ̂ afk ̂ 5Td dii i dndddit ddddd di ii c^ 15 fid dft aidfi ̂ itdd ddd - 2 i di if -^ct-KiPich di dRdfidj wi i ikt uHdit I , dd M SJM # • (5) d^ (4) c^ aiEftd ^ijddT di d fid dTfi di aiflmidd ̂ ddF didd (ddaiNit) i an^itchFi w i Miid , ^ ak dd^ fifidfdi sid? didd ̂ gddid^ i fiw M aridikd gdif^id aificpdd ^fidd i 3#cp ddikd dPd ̂ did i kr 3ifiM sdR ki di dkki k stm kdiduidT^kfcid^ d̂T 1 dt^’ql^d fifiRRf ̂ dJT dditR-17.

(1) TdTdd afk ̂ RdK EPedM ddldld k dTJddl dPd ̂ k did fid k iftdd dWId 'gRI ddd ai^^j^i) k ddidd ' k kd ^Idd f, di^ dRi Id fifiddd fkdi diddi afk ddd ai^^ i dkidd (ddiddf) di ddkaFi, dfi 31^ t, akRjf^ fidiT Fiddi afk ddk dddid aifkjddi k ndddid di dika k did fid di aidfi k itdd ?d anidi k dddk k argdR nsjd arfqkt k d^ d^ affdfM k fkd aifidnid ktdd fkdd fkdi

(2) damai^kdiddidf afNkkkai^i!j^fififkfMkMk.kkEftd#k 1 TfidH difkdi andk (dddkt) k antM M aifkdidd ktdd dd gdkeM dfidid difidj aiTdk k ddd k .aHEIId dd aif&didd ktdd dn gdk^FI cbwfrid fkdT ddddl—

(i) kk ̂ aik did ̂ «d -aik dkdR dRdM ddidw m dndddd^ afkfik kt ^ gdkfei kit t di ?d anidi k aisid aifiddid didd krad dRi di dkkd k dtd di ki dR, kt it d?k k ; ^ ̂ ^ fifidfdiaff kt kw, di ;MdM gRi fidd aid aifidfkd aifididd ̂ k ddgxR dfidid k dddd dT> ddk aifid? ktdd fiPiRfik k fkd ̂ f, fii?T kt diikf di dm fiwi ddkt k^ k fifidtdrai gRi d^ dfkdd di ddk aifim kt ddft kt df k ; . dmpTi I

18.

(if) 9qR(i ̂ WR : sraiwn[WT 3(ii)] cfft wsm, ̂ ^ pRicT arf^fcfi^ ^ ̂r^kr Rlci^id(iii) ^ M ^ ^ cfiH ̂ ^ ̂ 3Tq^ 31^^ RRRIM ̂ fki? ̂ f. R^ ̂ ̂ ̂ Rmn ̂ ^ RRdWoft ̂ M-ccfl't^ MR?ld TIT vJ'H'A srf^ ̂ <|(^ ̂ ̂ t I ^(^C|5^- TT^ (ii) 3jk TK (iii) ̂ ̂rakFf ̂ R^ ̂ cfkki, arRw^ c^ ̂ ?Tkki M. 2012 ̂ 3fk ̂ ̂ dwid^ ̂ aM ̂ Rr arR^fKRT cfJtro R- g^aM ̂ ̂ l cjjRttpj R 3f55R 3jRR R stRciKm ̂ m Ra^m- w 3tR?t ^ sRR^ R^tft to R ̂ tt^R) tR sfRRR^

19. ^ ift SRTOm ̂ RRkRR Rt ̂ RIRTO, ̂ el'icrjRd ^ SflcRTO R1 3itoTO RR^ ̂ ^ ̂ smR R Rt^. Rki ̂ ^ ̂ ̂ 5 R ̂ 3iRR ̂ siRronT RRci ̂ RR^ Rto Rt t 3(k arf^Rjf^ t ̂ , ^ ETO ̂ ̂ mr aiRronr ̂ ̂ RR^ ̂f ̂ ̂ EfRt cp^ R Rf?. ̂ R tot ■^, srpn-^^eRRl iR 31'i^iRra RRRRR ^ Rl+id Rt ^rrife^ titot— fi)\RTO^R RRR Rt^ toRt RRRRR R f ̂ stRtoh ^ RRtt ^ Ur RkTO#rl^ ^ ^ ̂ 3TRTO3T RR^3iRtoh|TO. Rtro. R ^R!RRfR3lfeTRt^l^TOF^RRTO^R^3fkTOT^^^.^^^^^^^ ^ WTOT R Rt^ 3TRTOrfT ^t5to TfRra R ^ tiRto R tot ot to Rrrn tottt I

(2) W)*n wfSi * 3«^. OTite ^ « If*^ ̂ R'Rtt?^ I 21 3rj#TT RRRRR Rt ^ ,.) ^ fliMtW * amftg aWM it ataflfe ^_jR^* ” fWifW * filftftfirat <i arafc ^ifiiw »rtl t RPiHfdi

20. Rt ttiRto ejRR Rk arjqfRd ^snRfi R WT-ill ^r^8nRar#Ta R^rf ^qroiRn 1 ^ M flRS 3mSra ftmsi m f»Wai, ^ ftp* wi ^ ^ ™ 1^-11 * aw- iv it'?Vra sflaawW W9,a art ft ftft arate ate« frt ft ftwl^ « ftE rt ft aftte aft6 ft ftft ftfftte rt a=Hfto ftft* ® R 3TtfR R^ Rtai R) ^ aik ^ aiRR RRti ^’Tcjtot ^3iRR Rkra RRroi 3tt^, i97922. TOT TJTOT- aitei ft aftfc ftrttera ft lftiaftrt^ft" ftMa. araraa a ftawft aaifftjftafta ft aate nw (,^,3 p^aa) afta, 1979 ft atestep w rt i[2R^tR, tot toh Rt tot ^

(1) TOTO, ^ sRsn TO toRTt Rt ^ sn^ R tttR tk ^ 3M?T RRcT toto igR to TfTkn afk RRRttt, 3TTtttto tit ^tetaftftftftteftiawwaftfteftftftfrt:«rtrt, aartal ^ TT^ 3RR RRtt TOcfTOT Rtot TOT, RR RT^ R, afk TOkr (1)(2) an^ R ttttoTO ^n tot 1^ TOT Rf^r R Rr toRt RR- cfRra R Ret RT TOft Tn TrsirkkR ■OTTOTTTT 3k T3TOT TfnfRcfJf?mTO, Tienf^, eR ttRettto tjto 3fk totoi^ Rt tR Rtro ttt 3tRR Rt RRt RTto er

(cp) RRhRt, 3TTTI1TO TJT totto ^r ^ R ttR^ R Rtv ^ Rttto TgRkTO Epk tl ■gETTO Epk R Rrq ;5ateftaftrti«ftft«aftwraOTftrtia,artftftr!3rt;rt7 Aa^ftteft afft^aftftftrtateftaiyfttewteft ft tei I(Eg) toto tot (TT) •krg Rto afk RRtReR ^r tot RtR /9^g (503'22- 10 . THE GAZETTE OF INDIA ; EXTRAORDINARY [Part II—Sec. 3(ii)] 3M?r gW 1979 alk 1995 aisfi^ a^iRiRltra c^t g^— 3TT^ ̂ 3TTTf^ gRi ^ ̂ amn^chl w f^RRcffr % TTsjrfMl TO? gT?I (g5^ m^) 3TT^, 1987 sfk 3« f^lTO) 311^, 1995 ̂ ̂ ̂ ^ ̂ 3rf^ m\f^ g5kn c^ crm jti^ wr gst ??t 3tt^ c^ srtfH gpn g^ srA^g g^M I

23. aRT f^rgg gfNg git ggrg eini, vixicoi ^rgggfg gft? vj^cbi om ̂ ^ f^, f?TO 3TfligKTg gitgg (gm ̂ g?^ Tif|g), grigro ijr ™ (ggciTR^) ̂ arf^igr t. tot ftMgr arf^rgRig grggr? gitgg (ggaiM) c^ 3if?TgRPT gitgg (gm TgT%T gr^ ?Tf|g) ̂ sfl^rgr g ̂ ^arg grVn : WfTf^gT'TO^TOTJ^mgkrafgRjggr c^ mto git cTr5te ^ Wn f^T ̂ ̂ g?- ;gi^rf?^ grW ^■^Igd RPintrd git ^rgg^r gitgg arflrgRTg ^rggrg gitgg (ggr rt^ ?gi%j cp^ 3#gj ^ ^ i

(2) TR^ 3T^ mm ̂ mg.^ 3TT?Tf?RT mm mg w fm ^ mm ̂ aggn ^ ^ ^ ̂ ̂ ^ ^ ̂ ?ng m?m gr ^ m gg g?T mm git mgrgg gm g^ 3TTgrf% sTtmig TTO? m gm mg ^^^jggg m git mf^RT gm I(3^J^ f^, TO a«, 3^1, ^ ̂ ̂ ̂ j, ^ ̂ ^ ̂ ̂ ̂

(4) jRm ^jggrg mm afk m^gj tmgtrn gRr m m? gg ^ ^ gm? ??T t % gm ggggt gg mt cgm c^ f^ - ■ ^ ̂ git mm gm i25. ^ arj^f^RT mrfmgt git gitgg m vjmt g>Ng ^ gg gtggm—

(1) jRm ^ 3T^^ mm mg ^ m anm mm m g? ?Rgg? grg to ir 'gg^ srmrnr m?T m gg ^ tmmr gft srfmmr' Tfggfm gm I

24. TRgg? ggj? mg; g? ggggi? git ??t. ggg? ^ mr m gfg TOT ■^, ggt mm mtt mggrg^g mg g? gitgg ?j^t Big fgei ^r mm mmg ^ m? 5?^^’mgrgif ' mt mg' mt ^ mg mm gr gitgg m gm ^rmp? mg m ^ m gjggg m git ^ ftroif m-TO? grg to-to g? toI^ gimt ^ m gwr vif ^ grgtggrogit^gggg RPtRRg'l tmg gitgg gg fi|g?iui mm. gg mg mtt mrmg git gitgg if mm gitgg ^’tt mg^, T^3Tfmgitggg?g^gTt; ^ ^ mmgf gg f^grm grm ^ mg— m t^TO mtt mm git ^ gigr-^ Tjgr gitgrr g? ^ mm git ggr g^ gm I

26. gr gm m gr aggrg ^

27. 3T^gRT gitgg rfr mrgr mrg mmi, amFPft gr mjgr aftm gg mg ^ ^ g# cp^_ 3Tm m ggrgg grgrft grmtgg, N gitf mggr m gig ggro mtt am g^ ^ am ^ tgmg gr mg m ?gg? g^ gm i

28. 1940 (i94ogg23) ^Bgggfafkg 5f^ ^ marmggTgggfm^aTmm m 3TTmRT ggmr git mg git [TO 3(ii)] TOT ̂ TITO3 : 3reHlR’'I. 11

29. 3rfil^ cjit WIT 3ik Mam fc^xj ̂ ci^rt— W'^1’ aTcRTcff <^f5dJict feni xn sm dr arraif^ 3ik ^ Mxr afNf^ cfiT uff ift HiHdi cPT arMxs' ■??tdT 3ik sik ^-aik tiwt? sm rr-rr XR d?TT k'5Rld ^ SIR 3iM?I ifr Rkn 3fR ^aWR ck f!tRft 3TMr X[ft RPT 3fk f^PlHldl k dtkR W arfiTk® Mam Mr xf5^ ?Tf^ M 1

30. tM, delT# 3jk StMir ?Tf^—

(i) ^TRdjR dT R3?T RjcfR? cpT kk M dwrM arMrk, Mr ^ f%M xjsnf^jfcr, dr wr . "awR ^ 1M Rsirm ^ Mr snM srar sif^r^ Mn -w ^ arjaiRd 'ijhf^'dd M m 3tw XlF RnXTH M dft ^ k kl ^ 3TT^T Msff XR ST^qraFT Mn w t—

(r) fM wr m jM gR Mn afk dMt k Mn ;

(fi) fM M kr, Rw M Tj? t f% ^ 3M tM Met rt Mejr Mr.^n t, fM RT t ttt Mrr M cnea t, xaM ^ arrEipfr, M ar anMr rM Mkr w siMr Mt maft t, ar srfkj^ dR Mn, 3fR ddl^dld. RIliricHEJ iTxrRMME^MMkrf^f^RT^^ Rdc|5t R;RTT M M aTraRR dara Mr I ■ ' . ■ -

(a) fM aMm, M M-M ar dETR-M, M-afM srk afMiat saa-Ma Mt stMei kr MM aiaa M aM t f% fM aM e^ Ma er Maa Mn aar t, Mtt rt a?T t ar Ma rt^ etirt t, arkpj^ eirreM I -1(6^

(2) aMt 3fR 3tM?r k aaM ts aMa rMt, 1973 (1974 aa 2) Ef^ aim 100 e^ Ma aar aaa, ^ 3oM E^ 3M dRraft 3ik srMmr EfTt RTEj I ^afEfR)c}R a?t 3tM E^'kr4, kasafkkaeE^ REfta rt^ Ejfr a^ Mft Rf^r^qaar ar aM ^ eziM Eak caM M Rf^r^par ar aM ^ gaMfrERi ^ M rwr ept aarM!r, REiara ^r M Rt^r^Jk^ e^ a^TRa Ek Mtj ^ ar rM gra M aa^ arar eM e^ Mn k a^ M e^ '4M rtM ert Mar M awR Mr Ei^ rM aa^, rtM aa rt^ ert Mfr : - a^ Ra^ ^ E^ REfia aaga M aa Ri^ m ^ Mr?aa M Rt^ aarM!r, fMt at sfMr ar R^'Tj'i^d RPiRfri er Ma awR gra M afraa k rIeTep ejMt aa, Rt arMaa Ejrtaa ar e^Mr aMr k asTrM!r, rMt it M# ̂ «m Et M RT^ Rett t i cpMa araat ^ la rM e6 RaaEtr ert rtej^ atf #tt— la 3tM ^ Raaa Mrfkfea ept cTpj att #Et, _

(i) aiafra ^tfe arMraa, 1970 (1970 er 39) (Rina tfe) ^ e^ at Mt at siMr M arjaEna a Mra E^ aiEaa a MM Ek ana, Rt ^ sfk RdiiRd a it, Raan Rirraa eM ark fM Mratar at af^ a^ ta t laEt aiRif^ai Rcaiaa Et araa at aM k ata a^ at Raft et? M

(ii) arata tta arftMa, 1970 (1970 an 39) (aMrr ^ REfta tfe at at Mt at sfMr an t?t srgaETTa Rk ftaaa e^ arsaa tr MM at at Mt atta aMn aiR ta t Rarraa aRt ark Mratar at ta t arkrMEP Rinaa ^ arta at artTi tr ata a^ ,at Raft ^ M

(iii) arar t iM ararR arjaTaa at artTi tr aia a^ at sraft ^ M aTjaaia sfk Mrt Et arraa k ftaM fM at akara aMt at 3icrtM aRt arkt Mt at Mft ER RRTaa aRt ark Mratn at: atg IR tar Et Raaa att tit Ra Rkft airftaaar (araa) k M R^ ^ffaft an arjataa aatt area att a-kfitR at RWR Et araR a^ga ftan aar 11 RT^taRDT—IR Ritm k rrM MtarakittiaktiRtREt aM Et M‘at Rkkr' an att r4 trar Rt sftaft Rk aRiaa anart Ma, 1945 at Ma i22R^ Et aiEfta Rk Mr aar t l

31.

32. [an.k. 31011/17/2012-tthll] k'g ERktktaR, kgaa afta 12 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)l (y RT.-msrftcfj, ft- f|#!T, ^ 2011 i flM : 1 -UoJiiJftifl/

1.1 BPJiosr sfk M?9I5?if gar ̂ ̂ ^ mmm fe, ?■mi iedisi jiftcT fs., ?. ?3M?rBr 3U$nhciil<n fe, ?■ 10 fezr. / fWk, 50 ^ (hci'nipm w., fe, ? JstteiW gfl?gg 3UitUl$B W., fe, ? SZVcftflolol ^■, fe, ? ?oM?for fe, ? ?cufcf?rgf 0.5 azi., 1 gz. TOS7 tzzto eS 3z# ggigezz ?sMm Sffui(Z?ZoZ ? ^■, fe, ? 1% 3zraH

1.2 czteer GgfldfeiW ?3r^izz' .11^^

0.25%, 0.5%, 0.5% te?Z? flftfZ

7.5% H^^fZ^r fe, ? BSx^lcJ sfffpm goof^fcZG i-Hlutnal

2.5%,inonhm BT?^lmk[?s 97., fe, ? 1.2%, 5%+7.5% 1%, 2%+ tZgioiieiigoj ■ I.-200,000 (etomivm bi^$}cMhi^g + CS}otle(l$at 97., fe, ? poufeZoZ «7te ^ az^ ?gz5EZ7 ^CTGgfZ? izfa

1.3 At'zI'JJ/ccJ 3ff^c^Er/o( igz^? pgfqisoz 5?!^ “ gg7.) 3zk M^z cpTo? fzz^ e?jf smmfh) M gg7 ^ ̂ q^ .qf^asr

97., fe, ? fouJcrtZoT , 0.6 f^. /f^ 5 fesz. 5 ftrazz. 2 ftw./5 5 Pm. ^Ppri pou[cz?Z5?Z7 ftzOTP mtfksi

97., f^., ^fezzufZTzsr fe, ? PiBl^lc^ 1 ft^ZZ. / 5

9Z., fe, ? gou)[/fZoZ 3{hm?at Hcqfe fe, ? goufcRZoZ 10 ftwz. / ftftz^Pmm?af 9Z., fe, ^ few 5 few. / 5 fefe ■"■' " oSS.Sf*”' ’TO * few <» !I5W 55I5,rt

2.1: 3iliqq,9.8 ipravafeEg I'ldMizz'd^ch 3<hr Wt^Vtficz t?IVbM 597 w crOm/M^ qW 9Eniw 5iizifel' .liiHcir cTaiT fwi Il-T3^3(ii)] 'ira ̂ ; 3raiVRni . 13 ■Mkfkfciiis# m., fS; if 325 Pm.,3S0 fimi. 'ms sitfmt 50• ? 25 fmi. / •)i\[ciiii 200 fmi., 400 fmi. 100 fkwj MkVI., fe, ? ftfW ^■, fe, ? 150 ^m. / yr., fe., $ 125 f^OT. / 5 ^ilfkci'itlel VI; fe'. ? 3i?#erar 500 ter. gl'y fe. ? esr?5«r2rrf>srte, srrfisr. 80 tejf., 170 ter.

2.2 silftijig-s XJ^ulRicr) .■raw 10 tejr. / /i)rf^ tewfoT Heite fe, ? 10 fter.arbiter gostersf 50 ter./ ter 50 ter.,100 tef.fe, ?pirm 50 / ter 2. iteBrraer fe, ? g3u/cr?rsr

2.3 ■'TFaC ^dlvjl qciigd 100 ter.fe, ? a/ter'

0.5 .ter.at/teriptesftfte fe , ?

2.4 R^j'A'eigs 4 Tigaa ^ ai^ ^ 50 ter.a/ter'mfmtm ' fe., ? 5 ter., 7.5 ter., 10 ter.arfterfe. ? 500 ter.atter ■fe., ? ?nte Tit fey ? aritef ■ 200 ter. 10 ter., 20 ter. 6rggk<!fl4et?flcrtffaf aSte/fe, ? V srjcRTwrr: ?gr ^ w ^M -TOaar I 'ter. / terssi^mVl; f^; ^usUicim 4 ter.arJftergr., fe., ?ttcilMIkil-Hl^di ^Ms

0.5 fkwi. / 5 terter^■, fey gmtis

0.5 fter.ar/terrgr., fey ? 4 ter. /pouJcTfror 100 ter.goxtorsrgr., fe, ?a?tear ggirMg . ri.

22.75 ter. / ter s ter., 10 ter., 20 ter. gsr^rargfy fey gt^terarrgar aitterfgr., fe, ?^sterMsr-'e 10 ter., 25 ter.aiWteTgfy fe, ?stf^aiuirgar 5 ter. / 5 terfter fllPToT <I)t rn^ 10 ter. 5 ter./ ter aittergr., f^., ? ter 14 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)] Tjfeste ajh 3FZIwi; 4 - # , Jimm gf-, fS; ? 3itm A jwaar gf-, fe, ? gl., fe, ? ?o^qf?fSr 1 ft̂ ./ Kfjfofe ̂ oW fS^jof l<[fntJc)oc; fSw <^[c^M3{ dcj^cplaic iii'^[i'UUni'Hl$‘!l iitni^c^d gr., fe, ? 100 fegr./ 500 Pm. 10 ftw./ fe-, ? pouJerefoT fksmcdk^it^ppi. -<teiUi$^ fe, ? . ^quJcf?fof ■ fe, ? 250 fe, g gsufegfgf sarar. sraifsji7gf so ftw./ ̂ pj ̂ m./ Mk ■ 30 ^ 250 ft®./ ftft

0.4 ft®./ ftft 25 ft®./ ftft gor^fof1 alftgaf ®?^ fe, g goi^for fe. ? ?ou[cr?f^ ojcnicfrtft g;., fe, g gcujggfBT goulg?^'mhi?? gr-, fe, ? f 2-ift?CT j viil^d g?t Ti^ ggi^ : VSl-i^dlcieiemtHi-rcet gr., fe, ? 200 fkmj ikfk [5 ftft j ’^rn : 5 - lif^toi'iqcitic/l'IS^Rf^fScm ggr/gi M ■ gr., fe, ? g® ̂ ̂ dilm/'it^ mk Mmm®tftftP7I?ar 3flft® „ ft® -100 ft®. 200 ft®. 100 IPf®./S ftft ft®®!?® ■ gr., ft., ? ?akcf?m S ft?®. / ft?ft ^ktmfkdct - ft., ? ■ ?akcf^m 500 ftaj?. / I^fft 30 ft?®., 60 ft?®. 200 ft?®./ ftft 20 ft?®./5 ft?ft 50 ft?®., 100 ft?®. 25 ft?®./ ftft 50 ft?®./ ftft 200 ft?®., 500 ft?®. 200 ft?®./5 ftft

100. ft?®./ ftfftr gf., fe, ? fe, ? gf., fe., g a?[ft?®' 5ot^?o? ft?® ktfkm gf., fe, ? 3?ft a?ft7!?/ ft??T?- pni^c???ff? ?7?fega? gg., %., ? a^ft?® ft?® ? ?akc{?[a{ !?iil4d c?lt ggiggt (??ft?oft??a? ? 2 ft®./ ftft

6.1 ??m ; 6 - [vpill--ign5 3(ii)] 15^ TTTO : 3raT»^R0I #

6.1.1 <<u^ni M 531 ̂ Wl ’^4 Mmm m., ? . ■„ 4tfcM{ ' 400 Pm. 200 Pm./ 5 Pifk Gei^Bgii^tcf 4 %llPld tfit ■ W., fS., ? dilPini 4.5 m. 750 ft®./5 ftfkTrJe^sfor

6.1.2 TjfePRclRilcf 337 ^331^31' . .>130137 . 50 Pm.V; fe, ? 3!tfe3fgr^ajt^ei^-ltrfqnggf

6.1.3 TjfefWiW 3ik Tjf^f^^ldl-s 337 ^ ®T W&m/4tit^^ .33r^7 .173337 37?fe37 . 600 -ftrOT.fe, ?^faf3^oE3

6.2 6:2.1 ^3Tel3CT 33T537 337 ^ Srfter/Si^i?’331^37 ."13S37 125 to?. A 5 tor 250 Pm., 500 Pm. 250 to3., 500 Pm. 125 tor. / 5 tor 500 tor. >H3£r7 3fk m4o'f[<>ife, ?itorflfeto fi^^rgcT >33S7 3f!7 Tn-tof^w., fe, 5 jJffufefoT 6 07773,12 51773 125 Pm., 250 to. 500 ton. 53T3?3?r^^3uns7r?s7 ^ou«w liPifRlkoi 71., fe., ? fCT^3?Jof 250 tor.,1 3zr.fe.,' $ fe, ? i^tpsrftto 250 to., 1 m.?oo?cf?rsrd<t>/$3l377k 125 tor. / 5 to( 250 Pm., 500 Pm. PmVI., ft; ^MctPtm <kr^ 250 Pm.. 500 tor. 250 Pm. 125 to ./ 5 f^rfe VI., ft; t F™/c7?[ar^Unnflfk<n Mkrs ■ 3nfto 33I53t 625 Pm.

228.5 tor./5 tor 600 Pm., 1.2 4tr. arttof >77337 3rt7 ?o5fe?rcr mkdfp{fcm+w^s^jvtPpp iPfs ? 100, 200 to.■ alitor^P?(km ?

6.2.2 3Rl .>73073733l^3f 250 Pm. / 2 torgm^irfrarfe., ?i ’' otopitor 100, 250,500 Pm. 100 toi7./5 PrPr ■ 500 Pm. aritor' 37>}o,, fox/lclVl^ ?ai3^cf^'[or • adtorr ■ pfiirsrtoto fe, ? iX ton./100 to^ , 250 Pm., 500 toar.nr., fe., gPiUheikilPl 6l$iUciUl$^ 80 + 400 Pm.,arfiornT Titoorar sr., ft., ? • 160 + 800 Pm. 40 + 200 Pm. /. 5 ton [ uc’prPrmuw'^lei} ' ^ ,, 100 Pm.aiitofgr., ft; ?sr357to5^to 125 to./ 5 tor 250 fto., 500 Pm. 10 fto./tor, 40 Pm. /fkfei 200 toir.,400 to. 500 tor./100 tor to "adtor?7.,:'ft., ?Gftaftrjftrar utcMc ptiu!cf?rorg7.,-.ft., ^torarrgto aritor ?ouicf?ror

37., ift., ?,A^fksi4lel . 16 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)] ftiw loo ikfk fey ? 100 ft; ? ’iUfkni 500 ̂ m. 500ft^.,1 W.?

6.2.3 591^ M .>13331 gr., fe, ? 50 Pm.,m ̂ m.mijpl tmtoi ft; ? aiWeraf 50 tor., 100 fezr.

13., ft; ? 3it7 3Z?fe?3r

6.2.4 Tffei5j;^'(tWlR('3 <Jc)l^3i isoft^300 ter. 331/31 31353 ?sii-n^dct gr., f^., ? 3f?ter' 200 ter., 400 ter., 600 ter., 80o' ter. 50 teg., 100 teg., 300 teir. 100 teg./5 tê Bitter gly fe, ? teg Bitter 100 tear., 200 teg. 50 teg. / 5te, ? teg 500 teg., 750 teg., 1000 teg., 1500 tear.>1133/0101131?^ gr., te, ? Bitter ■ 50 teg., 150 ter., 300 tear., 450 teg. 100 tear. / 5 f^tk fitg^/Bittegr giy te. ? teg gr., te., ? ?B</g?tor 0.75 4g., 1 iar.

6.3 3gTI3i 531/37 537 ̂ ̂ 3lfer//fiSEf i/W cte/tter /t te, ? goutelof 50 teg. >tete 100 tear., 200 tear., gat/^B11qlte1 gi-, te, ? otw 2% 50 tear., 100 tegr., 150 teBir., . 200 tear. 125 teg., 250 teg. 500,000 3rr/^ 100,000 3g/^ ' ge'^tplolioftei ft; ? ^g^ 3it? Bttte^f/ Btiilg^ettclol g^V ft; ? 3it7 Bjttter Blt/^31' B33?/ftBr gr., te, ? >t?gte

6.4 Tit'^3l3g^ 33lj3i

6.4.1 ljft?g>Stvit 331^3i 531/31 M 537 ̂ ̂ >/te ->135137 Bittegr 200 teg., 400 teg. 250 tear., 500 teg. 400 tear. / 5 tê ft; ? goutcfyiof ?rte?ior

6.4.2 1ffef^(i'l5l3'1d 331^

6.4.2.1 tert 531/31 itoft 537 ̂ ̂ 3^^//teg >15te -335137 lssiatl[iim ft; ? Bitterr 250 tear., 400 teg. gtte^aiggjc/ te., ? Bitterr 1=0 teg. c'tte^;si?5r+ Btfttai?<ii+ 5<tc.;i,?iggi et/^1-^Sl?cl+ [atsloHSl^<n 150 tear.+ 200 teg. + 30 teg. 150 tegr.+ 300 tear. 15 tear., 30 tear., 40 tear. 100 tear., 300 teg. fS; ? Bittegr f^stc^Stggj fe, ? Bitterr 35t 3t 33Tf3t »IRft : 315HIRI7I 17 •' j€^;si?5r + fe, ? ■ piMni- - 30' i+ 150 ft®.. "fe, ? Esv; ' •’ ''-'i i- 300 f^;+ 150 200 fkmt. mmn fqfsic^;gr55r+ ' ?.;1 Sj- • ?gr ̂ m

6.4.2.2 Aticidl 200’-,fimi^ 600 ftcyf.to'ftjcroi fe, ? 200 tor; so tor. / 5 tortô >rr5Br fe, ?

6.4.2.3 ggr ̂ A^siai fs.. ? 200 tor., 400 fPm. '■^*w ■:y^rS^ - fe-, ? ' 250 tor. 100 tor., '■■■ 400 tor./ 5 tor- -fe, ? ' 'Vi-- fe, ? 200 tor. -

6.5 <iciij<ri j . 6.5.1- ^ 44lj,ji[ ,432^ 591 ^ a&Vl/st^'^ ->r9Hcngnfertojgjiii^ ■r^ ?r., fe., ^ aittor’ 500 ftor.

3T., f^., ? torsrr 200 tor., 400 tor. 500 tor. /.loo- to-pocteror

6.5.2 tolfil fe, ?

5923.^,^. a^w/:^tor .>t9aar Btotor^ ^ go^creror 50'tor. tertoof 3rr?tor9to fe, ? ?oi^9?rBr 200 tor. 6r?fe9<rt fe, ? ^oxtojoT 100 tor.'/; tor

6.5.3 l?toc>ft9^%n59T

6.5.3.1 5cnvt fcHi 597^ 59r ^ ® crtor/^'i^ . ?re<sratefe+Trr9to8n3rr5sr ^ OT^r «<^J''( ^7 vr., fe., ? tor9r 50 rtor. ■ •■ 150 torr. ^ 40 tor. / tor , 50 tor. ■ / 5 tor ‘>l][htni pBi^rortteihJctMei ^}i4d torrrr., to, ?

2.5 torr., 7.5 tor.rrr., to, ? arttorryigari9ifl°r ,., 25 -.^. -arttorrwtorsrrarrgar , " rrr., to, ? arttorr 300 torr. 300 tosr. / tor sr., to., ,? . to., g c/tfitoato po53j5?ror 500 torrtj 25 torr,gr., to., ?am5kto+tortorarrarrgar VllPid at 991^9! i'"* 150, 300 torr.arttorrto., ?

6.5.3.2 jrtft>c)R^r« totosrargto. 591 ^ ̂ aiflq>(/sYti<9 vW59t/4t .TOerar OTto ^^59Tg9t 250 torr. toajitorrto., g

6.5.4 aan 99^ ■' y. ‘i : ■•; -. ,4^ -••'••• '-■*1■'••: 4-.' , t: 1: ■y i't‘ "-1 THE.GAZETTE#.Indiai E|XR4§RblTjlARY .■ ,. .. [PART 11—SEC. 3(ij)] ■18 M -.4 -r.- .igaar 80 + MO pm.; 160+ 800 40 + 200 Pmt. / 5 ■ ' ■' 'tlllhili- , ■ ■■- ■UiAe^M fPu *' \ \rv’ > fv ■ . 200 f^.fe, ? WT; 7 -

7.1: c^'fc^ ^ mi ^ ̂ ^miipii .’raaar sMcPii 300 - -350 ikw.udidimi ^Mkfkcp Nks ?r., fS-i ^ 1 fkm.^itfenutfe, '? ■ ■ ' otlfct'tl:m., fe, 5

7.2:i ill m Mm/'itM ^mi4^i mmi 10 fkm., -40 fkw.sdfkmAmoild WT: 8 - ^ wRiliji ^1 R^iRT cjcll^^i

8.1: mi M m ^mi4m M <>i]tknirnifkiihi^si 50 ftw.? ■■-'■^^''-Tb-ft®';; 25’#iwr., 50 Pm., 100 fkm.? ^ fep gmtefgf

8.2: liitlS'ili 100 fkmj fkfk mi4m mi M m ci&mi/'^tM ^ Jimrni gmiJcfSfor 0.5 Pm. '? foi^ra' 3 ftfa -ijgj 3n^? . PmPn^PiBr ^mAneisr 15 Pm.? BiiPi'Ui 2 ftwr. 10 ter./ cn^Ter 50 ter./ crr^r^ jfppdPsi peu)<ti[S[? 3ztter " goi^far 50 ter., 200 Pm. 500 -ter. MmeP^tppm^ 100 ter./ crrsTer soorPm./ mmi 1000 ter./ 0Mci ?rr?ette Mkspm^ ?™J<tfrsr? imptm 50 ter., 100 Pm.? poujirtrsr 10 ter., 50 Pm.? c^ingpr 100 ter. 100 terr./ 5 grst^? Japctim BltfePlitre^dtrfrigg 250 ter.? S.v<^h}iPiet got^for 250 ter. / 5 ter? 0]PiPt0 iiPis ^mAittlal 3 ter. / ter? 200 ter.i^stterte eiPslWiips poS^Iof? 1 ®r. 19 qRai.fi ; sTOivi^n'[«nn 11-^ 3(ii):] ; 5000 ^-1. m-cmrafSi^ ? 2 fkm., 5 §m.-i ■ -.diJfetdJt # rflmdol 50 tear. 100 ftjiir. / Bitfkm ?s^m r,'j ?■ ■

2.5 fW. 50 /^./ fWk sitlkm ? 10 to. gou}i<?[3r ?■ 30 fto./ 5 to' ? 50 -/to. ?S^M 5ou}cf?[or ? fcfoi^irffeor 'He'pti 10 ffen. ? 1 fto./ f^f/^ fysrfsPF^ 1 t6t ^ /'Sfp 150 Pm., 450 Pm. graef 500 Pm. gou/q^rSf gtruJcfSfof. tpiujalcot ' ?^tp(q/(^cr( 20 Pm. grac? 1 gr./2 Prlcim^ poxjJqSfof Mt^hdlPioT ? .Jou/cfSfSf ?3<ig‘pla‘Pi‘*tliitf 200 Pm.pouiq?[or ?toff 50 Pm. 100'/to.;' 400 Pm. 'PtPm , ■SUctUlcdPtl^ ? ? 2 to.sit/to ?

8.3: fto CISJT .'mar 5 /to. 20 to., 25 to! gs/fto' 3ik 60 Pm. 10 Pm.. 20 to. M ?gr 3dfePa fev ?4s/toto gou}cf?ror — PtPm' ■Msre/to ^ ̂ . 3?/fto ^qqetal Mddl^.' 10 Pm., 'ai/tor ■ ■■ 4 Pm., 8 Pm. , 2 /to./ PiPi ■ iiillkm . 'pou/d^foT ' fev'l ■■ . ' 3ifsr^s^^_'< 2 to./5 /to ‘-I' /to ^nftci <i5t ’it 1 /to mm 100 Pm. pou/cKfoT 3l//to■ /toSR^' ' 11^ 5gr ^ ̂ 3im: 9 -tdridf HtU^

1.25 Pm., 2.5 Pm. 100 /to.-l; 10 250 /to.-h 25 Pm. 100 /to.-h 25 Pm. uiPm /^., ? ^^tshi+ipil^sht ~ i>ll[ct<uim., fS: n 2 /to.■ 3i//to. Tir., /^., ? ^ B[ggldct/<!T?S .A .. ^ ■ the GAZETTE OF INbiA.: EX^iji]ai&iTOi-20 #.■u -'?SFa iSI&EI ticiijiii

10.1: niiUni Mmm mmpAmm3n?a[-- - r-fkw7/-fkfk-•> i ■: 60 f^RZT; MkS?tei-3lPr{S[-i^-■hav' ! / - TOfe-^rar--/i •j •-- 25 - — Hgfe ^mm)/ Mk i T ftw.-,;-5-ftwT- ■—j so ^rar. '3n^/-ftfe-~4 t •/ , Mks gr-, t^,:g - 1 SUigtsi jctn^ct ■ f^., ^ -rr ■: g7., fe, g ; ^ lo'ikw:-

10.2: ipnf^ gR^-cncft-gq^ ggr ^ jmm..-- L 1000 311^/ 5000 3n^/ ftfer- - fe, ? tsik^rsf fe, g go^fof 10 f^;/wd'iietirdul’n pstteiof 10 ftar./ ftftr -- -fe,-g dillcl’Hi 5 ft®. C^]<tillJl[icsl ~. • gm^cfgfgf ■ 40 ft®., 60 ft®. ' -1?:'© WTT : 11 - ^ ^aTT,;^|vi*||

11.1: 'ctlW ftwm . M 4ggr ^ .40 .70 ' ’ <cnT^ gi^v. fe, g ?5uk?for 'v :';io% g^v fe, g ga^fof 6% ff gouksfof 1'^ r: fe, ?icit-CLxl) ]li>A6% d[ef>)[m<n U Sfe, ?

11.2: v?irqft ^ i ggf ^ ̂M , :. 3.5%v; 55tRm 591^' jmmUeiQ^lkk fe, ? 5ovi?c[?ft- 5%, 20 %M'UilkPlid fS; ^ lo^Sfof ‘ftg? g™ <ftg? CT '“' wmkm ; ^Ph’^^hdpr ^fte?; "J: njjgnp 13JJ fe, ? %., ? p<k<fsr5t 3^ *^5^ ftr ■cfTof® fe., ? .C-y goofeR ^ : 12 -

12.1: ^ ->raHar 'iS ■i.- 21 } r-T.' uFUdlUd AlelPuli Ms W 75 ^m., i(»i#raT., 350 ikm. 0 o 37., .fe, 5 ajWefJjf i [hletHljJi fe, g azt%5?r ■ 30 . 60 tof. I MuilRcl . MeMm WlSiii ?s^m:

0.5 5 ■

37., fe, ? i .. .^//,.?. ■

5. ' ■ sr:, Mr? ■ ■■ -:10-#fW;,- 20-f^r mmt

22.2rvfai!TF(1^i^‘ .7 ft -. ;■ .-4 •■■ ' ^ k:VsMx^ "J~'•fw 25 ikm.,so Mir. 1 Mm./ Mk kihMci \

37., fe, ? pox^^ior ■ i.; i^Y'W.nPm 7^1 ^fy, f/ rmllkshiid- '■'■irmai: '? I2j2: xjfeRgPra; cjciig^ti ;=:4x.-r.-—^-..-.' 597^ ' jmrm T:Cf . !vf :~7>' loor^;2Dp ter. ■50 ter.7 'f^r3 ter 30 ter., 60 tezr. ST., ; ^axj{c[?Tm ;n i; ' ' -‘‘^Wpii .-K., ■i - ■ ?- iou?5?fsr 5 ter7' ter ui-nMct 10 Mm./ tergoujcjffor? [ei’imlvm M ? ■ 1%, 2% 250 ter. 100 ter./ ter sitter ^ct^rm uMdlJtl^S ? 40 ter.; 80 ter.

2.5 ter./ ter srtf^ • gCT^igrfe, ?terrte

12.3: m M mr n&m/M^<{<«/«r .ir^erar

2.5 ter., 5 ter.sitter3r., M ?■rmtfkftrm’ 50 ter., 100' Mm.mtMri, . 37., fe, ?U^oileilm , ??r . 2.5 ter;,'5 ter; ■

1.25 ter./ ter mifkm,.l. •i 'fc,'-. f ucniciiikci'kfetl/s. . g». .->1 cilniiik'mikfkrm I i'f gou!cr?i^ sitterf*-' ■'!t 25'ter., 50 ter.'■4- ■ 4.'’ - ■ 250 tef,sitter3r., fe, ?tei>T«slSl ^11^ Siifedit jiT^ ftteir sitterr aitir cgS'^oi' ^ 5 teir.,10 ter. 10 ter., 20 teir. 10 ter.,20 ter. te, ?m$<efkP[Sf mtMm ? 50 ter./ '5 ter SllPld r^t ^ cjciigiji

12.5, sitterr3r.; te, ? 25 ter. ‘22 THE GAZETTE OF INDIA : EXTRAORDINARY [Part 11—SEc./3(ii')1 -. - .I ■ ■ X: gcjquit) ̂ ?12.4 I'v/-' M jrmdi ' [sufTcpifloi

0.25J/%r'.' ;

0.25 0,05. \ fe, $ GfecKH . i

4. .V? :::-"'5o f^./ et»>§l<ieiJ<lgs i^'?r •:‘.x !?75?-i AO-Pm-/ Pkfk'-7\ni'p ■*) n : '■ .-p. ^. • I •

12.^: ■.{ ■ ‘2 nm ^ m /-WeRiT 75 / 100 ikm., 350 Pm. , 1000 srr^ / 5000 37R^ /; -pify 750,000 15, 00,000 . Mv. , "500,000 10,00,000 sRif; / ftrfe Upiciiiel ^[clPiPi^ ■ .wtfemi . .- fS; . ? ?Sifefgf.^HiPn. fil[s^>n fe, ?•U ? ^nWcT ^ Ttf. ^ ̂

12.6 gcni^ ■ UdidU-iPai fe, g s fir-gr.,10 firar. : 13 - i^ieMll^chd gcfi^ (^chH)

13.1: ~ . ^ ̂ wr oil^acAat Sfti •

13.2: ljfe$4!|cAicj ggr ^ ̂ irm Jmeldl fe, g 2% gm/etf U^invetlJl'i ■ PimmM^MkiPf . ‘iwjilgs E^o^SfoT Pi^]<nt^Pi<n+ iPf^ vtfiidlkfsmtfkar filedi 7[mifkmfS[Si mmifS; ?■ gfy fe, g 6^ 5% sffe 0.5%

37., fe., ?

0.5%

37., fe, ?. otPmkos 5 Pm., 500 / 3ff,37;, f^., ^

37., f^., g ofk'Smstkss

13.3: gan gcfif^ 5%-' 1% ^l/-37 fkc:iPisikPf gr^atfWsfe ^., 'f^.,-q S^£ snWaJcff - 0.05% W<!ii<Hi$<n 37;,- crfjfor • ' ■ ' ' 13.4: STffgTiTfe gcnsit . '. ' ggi/^TR... Pi^ atmaws . , gg7^ ^ dilm/'^f^ ist^ Mmm37., fe, g.

13.5: tmr 23 , '■ ['iTlJI lI-TsFTS 3(ii)] <be =,g\i , , ■ 2i5aarM■ 1 \, 5%.izr, fe, ?'cjsra are

0.1-2% ST^smfm ? gr„ fS; ^3e(rererft^ 5%.W:, fsl., ? gar ^ TO 5it?fsr

13.6^ jq^erai ' I !■ 25 %??., fe, ?I ' ^gjjfPfg ' .M, . 5%5^ fe, ?, , , T23?srte • 1%, 5%•at?rsr iIFT: 14 - ; ailiiarat^ c;cii5<4i14.1 ggr ^ Aiaai (fm^ 1%SiffiCT gk sma gk '321® cpI ^ fe, ^ 4% fe, ?fe/ciN}?^ 1% fe., ?g?.[?lipWl'gg'

14.2: ils'^l'ploiWiii *{l[s<u M. ^ Wl crf?^/sf^ 'pW M4eim ?argdl^ 100% s^/sftp 250% g^/cf??re%?f=rfe, ?; '■•' ■ 3pButefcffe,iMkim sfTgrttg 3irategf?^4^.4fes'‘~‘~’' ^3[c^3ji?^ .orratsciT^ ipo.fe®. 60% s^/cfl {smffksi - 280 Pm. / WgfJ 5-8 4ir. smtfksr ^ 100-250 .firfer 500-600 tor. / Mk 70% ^20 ft®. / ftftJ poxj}ti?[orfS; ^ smfku ^r^isr . fe, ?^TSIC^SH^Sl 3Il'’jIfJvilci Si. fs... ? ■r-'S fmjjtrersr 60% gw^/Eff cpctp, =292 .ft®./ ftftj,. 76% gyo ft®./ ftftJ V gnfeftsiteg f^-, ? ITPI; 15' tisn ^{fci'cif^tjj . I5.i: : ^ m wi-attm/tm J-: ■- '' ctrjiijaar •Mgaig® ,®., fe, ? fsn-TS Oetplfe 70-' ft'cptre®., fe, g - gl., fe., cT V, 20% ^ to 5% ^ to ^J HI., fe, ?

0.5%, 1%gi.,' fe, ■? 6%[?forgr., ft*., ®., fe, ? glggftg? ii\ctil[?S iiiftgft smlt^ 5%, 10% ■*. ■ 24: ■ ■ THE GAgTTE^F ; mM.QmMM .{P/VRTII—Sec. 3,(,i:i>1 •. W . ' M ’ ■■ mmi'X 30 % s^/g^ zmm ‘feMsr # a/rfidi? <p3r # [377^.^. sn-en? wj 34 tp?7 Hfe^?rBr cpt 100 HTSf grated cpai^ ^ 3776717 Wj fhei^s '^LCl mjg7 ,. '...W ■ i1 i'' |37'7.li} ■T ?7., fe, ? 77?e^?7oT ^c^cticifesigs Trmic^iicii ? . ^•, fe., ? TTte^fTsr 2% ^ ftn? ste^fTcf ^ R ’im : W -^^f^cHT ;c«<' ggr ^ qsr a-Rm/'itd^ tdfif wmi gout^for • ̂Ifeini ^^Hl'ltlpS w., fe, ? ! ■ 10 ft®./ ftft j_ . 40 ft®. 25'ft®., ■ 50 ft®. 10%, 20% ~ 25 ft®. ^T., fe., ^ ftft® <d[iiaic](n li-Ujailetdclat ^■, fe, ? goufeffff ?T., fe, gr ■ ftft® 17 - ^cii^ar

17.1: IJciRi-s ?fan 37® TffeHTTTTT HI ^ H' ̂ ciSmr/^fH 175®® uc^fk^rm 6l^^l'mi?s+ Hlkl^RPi TTiftsST®'■ . 37., f^., ? 37ftyiu7|® W/c/soJ

37., fe,' g . ' 37.,, fe.,. or - -.-— ,, Tnftcl ^ Ilf , 10 ft®., 20 ft®., 40 25 ft®. / ftfef ^orduK^lel ’Mfifksi 1 1 gCT^ft 40 ft®.37., fe, g■■ STtfcT® 20 ft®.

17.2: tife^ftfecRT gcirflrt' 557 ^ ̂ ^dtfkilisftiJRgft ■ 35e7® . 10 ft®. 1 ft377. / ftft . 10. ftwr. s ft377. / 5 ftft 5 ft®. / ft% 10 ft®., ■' ft®. 5 ft“J7./ 5 ftft 25 ft®.-/ ^

37., f^., ? ftlTT ^][kniddmt 37., fe, 5 ft7>7 gotjcfgfcf aitfcT® 7?ft<tt77 37?7 ftlTT gS^fof sftsTTftor 37., f^., ^ ft., ? 'v'"' 4 ft®., 8 ft®. 2 ft®./ ftft I ft®./ ftft ft® poftwr® ■••V ir--' [tIFI ll--®n5 3(ii)] 25TO ̂ ; TO’-Jin

17.3: ?5r w ct’Uf’i/ sY<l*?M mem ?nf5lei tl?t ■>1^ qqi^ili’

5.p^f^ ^(k[h[k<t> ifies ; s.tofe fe, ? 400 fim.

17.4: cjcll^iji mi ^ m ciifl<pi/sYdt?mi^m mem 10 fk’ui. 10 ter./ ter 3rf/(^?rr’ ?4ufir?ror3T.,eifs^ecihi^s ^f(WI jSoijJcffrof 10 f>mn. 20 firm./ te-firr., fS; 5,enikir^m c^prjer ate^

17.5: aar ^ w eiitm/^i^miiai mem 5 ter.terar’ wv/teiSar., fe., g m, fe., ? ■rlo^rtr$i-maieii

17.6: §5tra ferj ^cflfJIT

17.6.1 :g®M Plvjicfltr^ITJT ?iaDT aar ^ ®r ci&m/it^^MMlaai/ar iiartctr scjaitTr.' 13.5 m./ uer. nih^jr nertms: 2.6 ■ m./ uei. ikilirm wetkr^: i.s 4rr./ era.Trlc^froT te arnsTar.i ^sfreer ffera^fror Tfe" srMfeaw Trr?^ ^r?mie+ •■

2.9 m./ner. 2ooter, 500 ter, 1000 tea, 3?' fkn wise ^n^.il. ^ oaerr? a7j

17.6.2 I . mi M m wSm/tf^ - ijiifira tj)t aarfat M ?a^aatffai 20 f^ir IS fterftrwHT., fe., ^fiiiip 7?^ 1TFT: 18 ■ ?TRf^, 3Rf ^aifTlf 3ik aif f^«Tc8

18.1: xprf^jaet fmta aik mi ^ ̂ U,^.ClClLMt

0.5 terr. 4 terr./ artfeaf fax^mfe, ?iaOTftaiuffe 6l^^]ct>](Siitei «J/sa-a mtMu 100 .ten. / te^$ax^TSf5T., fS; ? 40 fkm./ Mk 5 tear., 10 ten., 20 ten. pouia^rsffe, ?f^smei i^o{lnM<n arttennr., fe, ? I8.2: aar ^ tw uactdfaai^ar 40 tear. HsnsrJ 25 ten./ f^rfe frtfttek TrrorJ , nr., f^., ^ poul Iff tBT

18.3: telaa) fcjqS.^ll3 4^ 26 THE GAZETTE OF INDIA : EXTRAORDINARY [PART 11—Sec. 3(ii)]

18.3.1: ggr cl°i ̂ aflm/ iraridl

0.03 Pm. + 0.15 ter. r+ w., f^., ? . aitter 0.035 terr.+ i.o. Pm.spwfhP^iilcj e}q?oiIto)i^|e; plJ{]zlat dcilciico^i^lci PPtptoi) ERH]<n tefter 317^^ ? 377^^

18.3.2: vlMchyui ggr ̂ rppR ^■, fS; ?

18.3.3: gar ^ g7 ysraar '0i<!isi'n ^■, fe, ?

18.4: gar^ar gar ^ mr ccSm/'it^ F yasar

0.01 ter.

0.05 ter. yr., fe,- ? artftraf

18.5: yaaa ga^

18.5.1: 3tty 3}^ T{^ ̂ 1^ gar ^ ̂gai/ar' . yasar Plfet^ 2.5 ter., 5 terr. y?., fe, ? arftef(^m^nips poster 5Su[a?ror f -itlc^ctd] {el<^ / Uai'Uuu yr., fe, ? pox^iof 40 377#^ / ter yr., fe, ? pn^ra' 40 377^ / ter ateyteior yr., fe, ? ^HfcPn 500 ter. ante a5I ti^ garfaf ftfttew pagte 30: 70 poterar yr., fe, ? pButefoT 40 srrrf^/ ter

48.5.2 iji^M'iPic!1Ri<i<4i 5einjt ^^cHi aa^at gar/ar M yarsar ? ?30?a?(or 1 tejr./ tey yrite t^I aarfat 25: yr., fe., g pBuftf?pr 100 ter

18.6 artaelyFr ^aa^rry gar ^ ̂ aifer/g'te'gar/ar’ yqerai 50 ter., 100 ter. itcilPt^ arpijd arlter

18.7 gar^ar' gar ^ w dilm/'iMw ya^ tej^oT ^tea yr.', f^., ? 5 ter., • 10 Pm.ter/^rftate ^., fe., ? al/erar 5 Pm. 27TOi ̂ : 3raiw>i[«)m II-^®3 3(ii)]

18.8 ®JT5^1?3 afrf <c|^«T mMm c[&^/itM ̂M mcicu 5 fkrni., 10 Pm. oilfk^VI., fe, ? 50 VI., fS; ■? ■’ odfeini 100 ^ 8 Pm. / 5. P[fk3u^\(k<n 3Tm: 19 '{VlMf?l'(l{m 19,1: ^5iPra> TJute” 591 ^ w ^ y^dciiMS&vftpif siftof iMfecf pou}(t?for5r., fe, .?.

19.2: ^ TraaarsMiPii 557 300 55§?T^5?ra'fe, ? 10 ^5i^5?iorVI., fS., ^ •iJ/etdcloc ucflt-oiv ^®Pf 250 3TI^ 500 311#^5<^5?for37./ fe, ? 10,000 377^fi^9?f37fe, ? . JftiH ?'KjloiJ''<?l]ft<'( 150 37l!^^- /ftfe5i^5?7=737.,' fe, ?

19.3:

19.3.1: uf^tcR^cT ^ 3iR|3«13T 557 5P7 t7^te7/^fi^ t’Y'tf 353777MsttvPPli ?^rsr37., fe, ? ?ite7sr37., fe, ? ?<^5?75r37., fe., ? , ■■■ gj^Tgf37., fe, ? 37773 3tfe757375^ft77 dft7«3 UcHj) 77^5^773737., fS; ?

19.3.2: ctjIcRl 57t 1^ 557 ^ ̂ cC&^/'dt^ ■ ?ot5?73737 353777 aflwPm ., fe, g

37., fe., ? t&27 dfe?73 5o?c7?7o7^2377 dvm?s l^^cFfe Xif^) 3ik TStfel^^!^3775: 20 - 557 ^ ̂ cCft^/'st^ 353777 10 Pm. / 15 Pm.,

0.5 Pm./ ftrfer 60 Pm., 1 #737./ ftfe .50 f^./ Wk sitvPpa 5ok?73fi?., ?9757775^ sdfkvt fS; ?PrvtT^tw^im 37?fc757 ' ?ote7B7fe, ?■muPdlPdcrtJil^oj 7757fl3753 53?3gg ?3t5?75ffe, ? 28 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. Sdni ^■, fe, g 2 ikm./ Mk ’ini : 21 - aftTOcRtciff^IcBa ftfSrfJJRtuf

21.1: Tfwis gar kk ^ggz^ ygirfctr fe, ? '^/ sikmskss 0.4%, 1%iiiukeiUittm

52., fe, 5 §t5/3iT?fgfS3[oe- 0.3% ofogTOgffer 52., fe, ?

52., fe, ? 5^2 0.3%ft<p(oi(o(Ie( I^2 1%nllhsk fe, ^ 5^2 0.6%\iic>Pqcirf((ps kl[kn-H 52., fe, ? 5^ 10%, 20%

21.2: tpjtg ggl^ msm^seUnleii^

52., fS., ^ 5^5 0.1%

52., tg., 5 5?5 1%

21.3: ~<Hlci)cl ^ kA m wSm/'sf^ggi^ 5geJdl ^?;icpoi

52., fe, ?

0.5% : I'iid'lfoi) tian ggrg^ ggr cn!ter/^ijg~^

21.4 532^52 aUtCMlcu-ni^s fs., ? 250 ^r.4cicr«l«!ef miUeiklfS ? 0.25%,

0.5% fterferOTTgof fe, ? 2%, 4%

52., fe, ? S^f 0.25%,

0.5%,

21.5: — 332 ^ ̂ §?5/3iT332g3fer czhi$tn 53c2sr52., fe, ^

52., fe., 3

52., fe, 5 1% I^2fksirUelPPiPTSf 2% 5%21.6: 3l1wf^ ^ ■ 5uf3?2o2 332^ ■ « 33332 •? . 2% : 22 - 3TlR5!irilRi>H 3annm

22.1: aftf^retRm 332^'

52., fe, 332 ^ ̂fkstrsm uisitkcra?s[ mmi '^kfkm 0.125 f^. 291TO ̂ : 3rai*-wn -r Cfi

0.2 tor./ tor 200 1km.ktfkmsrrtotek ? 5 3rr^ / tor, 10 3rr^/ torito?rorfe., ?sfmfktfkoT 100 ̂oil !k til(kuMidci

22.2: rraeicrr

2.5 to.

0.5 to./ /tor storJiT gtorBTfe, ?iitJidifkm Hto ?nto cfit ■nt tj^rnpri 10 to.ktfkmm?wfkftiw 4 to./ /^/^ar., /^., ?lkci[ksii<^}<n ?tm: 23 - -dirjf^Rrfr a^rtcirM.5®^ 4 er^rsrar^o^iiiakllkni^ ? ilFT : 24 - toaito ^24.1: ^ Hk m crSm/ktk^ ^ WeldlM 25 to., 50 fkm., 100 to. 25 to./5 /tor 25 to./ /tor 5 to./ /tor tor® g5r/torrr?r?sr fkmm., fs., ? ■ Z^-, gtatotor Tirto nt cjcti^ni 5 /tor., 10 fkm.kffkm3del<ni^i'll?‘n ? ^ ftoafr^ rigrra 3®?®24.2: g® ^ ®r afl®r/^f^ ai//tor

24.2.1: iraaar M441?® 25 to.m., fe, ?cfto^ra^ 20 to.■retj^u/irticKl ®., fS; ? sifg/wil 25 fkm., 75 to.rtp& oijfattl®- fe. g . , —— 9^ 2.2: gratoR ttoan^ A ^4T5® ^ ®r vKk oilfcitii g agctar 300 /tor. '4®^ ferik^ g’W/cfe' ?nfto ^’T? 200 fkm., 500 /tor.tor® ®., ft; gw]/^<CT toaite 30 THE GAZETTE OF INDIA ; EXTRAORDINARY [PartII—SEC.3(ii)1 if\ 24.3: 31PT yqiRT ggf ̂ ̂ ^ T/leidf VcW^itePI 0.25 Pm.,

0.5 Pm. ST., fe, 5 ^feprt 2 ftt., 5,ftw. fe, ?

24.4: t%TOTT;^ tr^ ̂ fjiftT I I ggr ^ ~| ?nWof nit Tif mmm 'tc^dlkac<H W., fe, 5 • 20 ’^1:25- cli^ cn^gcTT^Jlt

25.1: gcfT^ ggr ̂ ̂Mtiui4m VUeidl(k<P(nlPiSiii^]t!t ^ulPtuMd ®r., fe, ? 50 250i^ijfl / gti^ . 100 Pm., • 200 fW., 400 Pmi. 2 Pm., 4 ft®. 2 ft®./5 ftft 100 ̂ / gftw., fe, 5 ftw rfef^pisrfer He<^ ?2., fsl., ?. go^e^ffof ^nftcT ii>t ^cn^ui gf-, fe, ? 20 ̂ /afeg gft-

25.2: ~ siffem HI mmt ■Plfsol fe, ? 10 ft®. 15 ft®./5 ftft 30 ft®. ft?7 i^njiPispTH gf-, fe, f ^\fom 26 - Pte^, cfsn XT

26.1: aiRcI PPI^ ^ H m d'Rtpi/ifH memg2., fe., g gra^ 3?ft Titmm

26.2: ~ ' 3t?^ V? ^ sfren? PPI^’ ^uJtrer^ waargg-, fe, ? 5% snMdPi, 10%, 15%atft2w ga?agg Hfta 32., ? 5%+ 0.9% aYrf/et ^eflggr GBre2 jlrtiScj

32., fe, g

0.9%fe, ? c^ies Hi^<n gterf^rwa gafagg ftg? eJtflid fe, ?

32., fe, g n.2% 3n^ »# ^ aaemr g? 3n^ tfl ^ aacfi? if?

32., fe, a 5<^p?ra

32., fe. gojq^fof

26.3: ^ fee ingff ^uj<t?f3r Wridf i ftfe, 5 ftft. 10 ftfiir32., fe, g [im 11-®M 3(ii)] 31 6^^ WT: 27 - RdlRlH 3ik . mi M m wSm/^tMMmifyi UHdcll 100 f^m., 500 ftm.^■, fe, ? ^’dfkm6ftis 250 Pmi., -soo firm.^Tim ipraM? gr., fe, g m wmm sjMkm ^ z ̂ snoR W

52., fe, ? 50 PmI.^IfePn■gf., fe, ?[krp][i.<ni'Hl$^ 'iillciui 25 Pm.gf., fS; nmuPdlwiftsi 5 PpSl.g2., fe, ^Pftetlcld mnPiof ■ 100 Pm.52., fe., ? ■ 5000 322if% 50000 322i-.^^ 100000 321f&5^g2., fe, 5PiziPm U ■ 50000 .322^/ PlfP PiziPm ^ ; moi)$fc^U^del^

0.25 Pm., 1 PPir.f&5^ girfijef 2^^ fit

52., fe., ? 100 Pm./ Prfk ^ io 2'a5-^?1^5?2BT52., fe, ? Jf^fe?RW acj<p|o}d 3T^-2 SgiW-1 ra p)WR> ^ grafira ^ 3Tt^ cBT f5m2R/g^«w 3n^ gn litwrf . [%I 2 (^) 5,7,8,9,15

1. cf5T ^ sfk w : f!tqgH cftiT^ cf5T ■^, 2Tl^ cf5\t--^ : 321^ Praw gM affg ar^ffifer et^ ^ ar^giR g#f9rgi : ■ sftEffgf arpTT gfgsjtcp sftg (jrfiT ^ : -dcqi^/3TT2ITd ^ f?rf»f ^ WT/^ 3TTf^) : ^ c[5T 3TT^ (lOXTgT/iOOTJgr/lft.cft./ 2Rcft. / lOR^. /5TITH/103nH Sflfq): RPi'Rfil ^ 'vJMdlg : f^racPT/g^OT ^ ^ ^ ̂ : cif3TH i i

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12. 3?Tf?>^ f?tna3^ : WFf : ^ : : cTT^ : [Part II—Sec. 3(ii)]THE GAZETTE OF INDIA : EXTRAORDINARY32 ■315^-2 wm-2 .. RPiRRiiit cjn ^ (1^16^) ^ ̂ sfk'WT :1. cpT ^ 3fF? w, cf^rt t:2. '^r arj^jpid RiPlRlci/ ^ ait^fEj cf)T ^ cItIR50TI0 RPiRIa afk vj'tinil Tpicfj cfir 3nq>K

(1) (2) (3) (4) (5) “~2S~ZnS25CK'3Tg^|txRT IqHmid Tq RPiRd ftprfj^frRTT RTJT -qt/anriTf^ l^rMcmr arf^WR ■gsETirT cf?PT?T (t^. aftr T?f|d) R)TT^ trr ^0(f.^.Tlfld) (^0) (^0) (srfE^qpm) 3fk (^0)

(6) (7) (8) (9) (10) (11) feq^I5T_:-sPJT ^ -qf f^lPiRRl ^ fclPlHfdl RiT ^ Wdf^ld fctnrT ^ifTW I dM'ddd if ^ 71^ '^Hchl^l if^ TIcifcR' stH affT i?r?c[RT % ^ 3ik TCT t I d ■gTdTSNwt : WET : qm : : ■RRti ^ : srervRni .33 3T^-2- WT-3 ^ afr^w : f^WT citTrft ^ ̂ afk w, ^ t: W ̂ f%HT^ v}rtldd/3Mlcf aik fcl^ ^ sff7 : — w?Dft-3r

1.

2.

3. 3I RRRRl ^ JRi'T Wira=T/3TPTra cfJT ^ {3lfO/fii.3n./f^O) •^aft f?mT^ fcWI^ fimif

(1) (2) (3) (4) (5) (6) (7) (8) . (9) ’Eftaft Rmr^^ ■ ^ fcmi#

(10) (11) (12) (13) (14) 33rn>ft-3n ^44 nRledlRd- STOtf^ftffitcT 4f ^mfiT f%IJ ^ artgi aft^ c(5T VjCMiq'l/Oil^ld ^ 'W'^ (f^.UT./^.) #fr51'Tfaft fcmr^f^mr#. fipnf aiPT

(6) (7) (8)(4) (5)(2) (3)(1) Encja^ , (fki4t f^ar# alaft fitarfla?cft fctai^

(12) •(13)(11)(9) (10) 34 the gazette of INDIA : EXTRAORDINARY [Part II—sec, 3(ii)l gp SL'* ^ ^ I WH : cn^a : «■ ^ ; T^^TR : 3T^^-2 ^ :5rw-4 [■^ 2(2) M] f^P fen? sfwrf iRfrr cpr ^ ;1. f^^^PTl^/3?WrcT^ cfji 3jf^ ; 3TWgr f%4^ jrr^prRjff gRT grarfK

2.

3.

4. T 3jk arjffrfef ^ 3tjhr ; jTflrasm SIJS, ^ 3#, ^ ̂ ̂ . ^ gW 3fk arf^RjcRT cfft :

5.

6. STflmKR ^ ^ 3T^ jjgrf ;

7. dl'3'W ;

8.

9. ^^wr/3TRRT ^ cfft Tnikj ; ^ ̂ JRtTTfcfcT rTT^kj :10.

11. ^^TTg^/STRRT ^ «ig cfR^ ^ cpRDT :

12. ^ ̂ ̂HflcT f?r0^ 5 cT^ . er^cTRf^ . 2013o^3TEft^"^3^-^,^^ 3TW?r 3TTWcHt7||f ^ Bfg cfR^ ^ ^gr gj)f 3?RT RPJcPT?) ;

13.

14. ̂ ̂ ̂STHT^rf^ gflf ^ ^ ̂ ̂ ̂ ̂ arraftcf t \

15. ^SJR ^FT :cfllte ; WTFT : [*im ll--0^3(ii)] »?Rcl ̂ TTSm ; STffltlRq 35 JfWT-5 [^ 2(x) 24,25,26 ^ ̂ 3?t7 W :1. f?rwT cfMt M ̂ 3ft? wr, ̂ ̂ t:2. ?n?Dft-3T ^ SIICPKgio^fo 3?ggr gr gig (RRRRi 31^ isggft <5'iicu gg 3M?r Pig^i)| SRI ^jggRf^^ git gitgg. (iiit.gftg) Slf^chdH jcgiy ^^tgg (i#. 3ik gR JRW) (^) gf|g) (^)

(1) (2) (3) (4) (5) (6) ^ filPiRd RRRRdi g>g git g^ angiffm RRRRigi ^fTT^-STT c!?! GTTcJJRdfMid gg gig (RRRR 3tW gggft 7|^ig) gg giogo afrgflr Rggig jgftlcpiRi)) gRi ajHiftd gfSwR gsggRR^ ^tgg (tiit.gfig) sifsiggig (t.ii. afR gR gl%ci) ireg) M M

(1) (2) (3) (4) (5) (6) ^ 31 j-jjRid ftPiRRi gg RRRg RRRRgi gig g>t g^ aggiRg RRRRi ^utptmr :-wj g5f gf RPiRRr gtg^ ̂f, RPigidi gg gtg ̂ ggRra ftjgr gmfgr i ^g'iW ̂ ̂ gf gggggt ing sft? f^?gm ̂ ̂ afR' ̂ t I giRt^ ■g^diSRggrf gpT gggjg WH : grtte: J 36 rHE GAZE1TE OF INDIA : EXTRAORDINARY [Part 11—Sec. 3(ii)i MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) ORDER New Delhi, the 15th May, 2013 2) ,rr" ■'’9 “-SMPrte com™,) order 20,3( ) come mto force on the date of its publication in the Official Gazette

2. Definitions.- (l) in this Order, unless the A context otherwise requires ct, 1955, (10 of or omitted to be ,-

(a) "Act" means the Essential Commodity Act, 1955 (10 of 1955); pr!,dSTn7ud^7“'eX‘'|^^^^^^^^ biological or plant as distinct from thoseTothSl^s;'^"' °^ber feature that identifies one seller's drug ° <» forme, mcordance w,.h .ho

(f) "distributor" or sale of drugs, whether as g wholesaler or of drugs and includes an agent or a stockistfor dr„;;or ̂ riToaTor"

(g) "existing manufacturer" Gazette. means manufacturer existing on the date of publication of this order i in the Official

(h) "Form" i

(i) "formulation" means a medicine processed out of p armaceutical aids, for internal or external use for disease and, but shall not include - means a form specified in the Second Schedule; or containmg one or more drugs with or without use of any or in the diagnosis, treatment, mitigation or prevention of any bonafide Ayurvedic (including Sidha) Unani (Tibb) systems ofor

(i) any medicine included in medicines; (») an, medicine Included In the Homeopethic svc.em of medicinepharmaceutical Ingredient contained In the formuladom Whlt^ name or the name of the active

(k) "Government" means the Central Government; and name; “Sit 1?;^^ means bringing a drug into India from a place

(m) "local taxes" means any tax or levy (except exci the Government or the State Government manufacturer or his agent or dealer; imgsrSrrt;on°orsareK^^^^^^ manufactures, i or imports and markets or percentage of price to" retailer; to a drug collected or obtained by the Government as ['Jm II-'!gTS3(ii)] HRcI ̂ 37

(r) "maximum retail price" means the ceiling price or the retail price plus local taxes and duties as applicable, at which the drug shall be sold to the ultimate consumer and where such price is mentioned on the pack;

(s) "moving annual turnover" in a particular rnonth means cumulative sales-value for twelve months in domestic market, where the sales value of that month is added and the corresponding sales of the same month in the previous year are subtracted;

(t) "National List of Essential Medicines" means National List of Essential Medicines, 2011 published by the Ministry of Health and Family Welfare as updated or revised from time to time and included in the first schedule of this order by the Government through a notification in the Official Gazette;

(u) "new drug" for the purposes of this Order shall mean a formulation launched by an existing manufacturer of a drug of specified dosages and strengths as listed in the National List of Essential Medicines by combining the drug with another drug either listed or not listed in the National List of Essential Medicines or a formulation launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as listed in the National List of Essential Medicines,

(v) "non-scheduled formulation" means a formulation, the dosage and strengths of which are not specified in the First Schedule;

(w) "pharmacoeconomics" means a scientific discipline that compares the therapeutic value of one pharmaceutical drug or drug therapy to another;

(x) "price list" means a price list referred to in paragraphs 24 and 25 and includes a supplementary price list;

(y) "price to retailer" means the price of a drug at which it is sold to a retailer which includes duties and does not include local taxes;

(z) "retail price" means the price fixed by the Government for a new drug under paragraph 5;

(za) "retailer" means a dealer carrying on the retail business of sale of drugs to customers;

(zb) "scheduled formulation" means any formulation, included in the First Schedule whether referred to by generic versions or brand name;

(zc) "schedule" means a Schedule appended to this Order;

(zd) "wholesaler" means a dealer or his agent or a stockist engaged in the sale of drugs to a retailer, hospital, dispensary, medical, educational or research institution or any other agency;

(ze) "wholesale price index" means annual wholesale price index of all commodities as announced' by the Department of Industrial Policy and Promotion, Government of India, from time to time.

(2) All other words and expressions used herein and not defined but defined in the Act or the Drugs and Cosmetics Act, 1940 (23 of 1940) shall have the meanings respectively assigned to them in the said Acts. .3. Directions to manufacturers of active pharmaceutical ingredients or bulk drugs or formulations.- The Government may, -

(i) with a view to achieve adequate availability and to regulate the distribution of drugs, in case of emergency or in circumstances of urgency or in case of non-commercial use in public interest, direct any manufacturer of any active pharmaceutical ingredient or bulk drug or formulation to increase the production and to seli such active pharmaceutical ingredient or bulk drug to such other manufacturer(s) of formulations and to direct formulators to sell the formulations to institutions, hospitals or any agency as the case may be;

(ii) for the purpose of giving any direction under sub-paragraph (i), caii for such information from manufacturers of active pharn>aceuticai ingredients or bulk drugs or formulations, as it may consider necessary and such manufacturer shall furnish the required information within such time the Government may fix.

4. Calculation of celling price of a scheduled formulation.- (1) The ceiling price of a scheduled formulation of specified strengths and dosages as specified under the first schedule shall be calculated as under: . Step 1. First the Average Price to Retailer of the scheduled formulation i.e. P(s) shall be calculated as below: Average Price to Retailer, P(s) = (Sum of prices to retailer of all the brands and generic versions of the medicine' having market share more than or equal to one percent of the total market turnover on the basis of moving annual turnover of that medicine) / (Total number of such brands and generic versions of the medicine having market share more than or equal to one percent of total market turnover on the basis of moving annual turnover for that medicine.) Step 2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below: P(c) = P(s).(l+M/100), where 38 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)] P(s) .= Average Price to Retailer for the same strength and dosage of the medicine as calculated in stepl above.. M = % Margin to retailer and its value =16

(2) The ceiling price calculated as per sub-paragraph (1) and notified by the Government shall be applicable scheduled imported formulations also.

5. Calculation of retail price of a new drug for existing manufacturers of scheduled formulations.- (1) The retail price of the new drug available in domestic market shall be calculated as provided in sub-paragraph (1) of paragraph 4.

(2) (i) the price to retailer of a new drug, not available in domestic market, shall be fixed by the Government on the principles of "Pharmacoeconomics" of the new drug, on the recommendation of a Standing Committee of Experts formed under paragraph 15.

(ii) the retail price of such new drug shall be fixed by adding sixteen percent margin to retailer on the price to retailer as fixed in item (i):

6. Ceiling price of a scheduled formulation in case of no reduction in price due to absence of competition.- (1) where the average price to retailer of a scheduled formulation, arrived at as per the formula specified in sub-paragraph (1) of paragraph 4, has the effect of,-

(a) no reduction in average price to retailer with respect to the prices to retailer of the schedule formulationand ' to

(b) there are less than five manufacturers for that formulation having one percent or more the ceiling price shall be calculated as under:- market share.

(i) in the event of other strengths or dosage forms of the same scheduled formulation is available in the list of scheduled formulation, the average price to retailer shall be calculated as under: Stepl: First the Average Price to Retailer of-,such scheduled formulation i.e. P(s) shall be calculated as under: P{s) = P^,{l-(Pil■^Pi2■^...)/(N•100)} Where, Pm = Price to Retailer of highest priced scheduled formulation under consideration. P, = % reduction in Average Price to Retailer of other strengths and dosage forms (calculated -- in stepl of sub-paragraph (1) of paragraph 4) in the list of schedule formulations w.r.t. the highest priced formulation taken for calculating the average price to retailer of such strengths and dosage forms. as N - Number of such other strengths or dosage forms or both formulations Step 2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as under: P(c) = P(s).(l+M/100), where P|s) = Average Price to Retailer of the scheduled formulation . hereinabove and M = % Margin to retailer and its value=16 scheduled formulation is not available in the ^rhpH H f ^'^heduled formulations in same sub-therapeutic category as that of thescheduled formulation, then the Ceiling Price shall be calculated as under: Stepl: First the Average Price to Retailer of such scheduled formulation under: in the list of schedule as calculated in step 1 i.e. P(s) shall be calculated as P{s) = Pm{l-{Pii-^Pi2-f...)/(N*100)}, Where, Pm - Price of highest priced formulation taken for calculating the the formulation under consideration.. P, = % reduction in Average Price to Retailer of other schedule formulations (calculated as in sched.^P^f '"'Tr sub-therapeutic category as that of thescheduled formulation under consideration calculating the average price to retailer. N = Number of such other schedule formulations in the scheduled formulation under consideration. average price to retailer of w.r.t the highest priced formulation taken for same sub-therapeutic category as that of I 1 [HPi II--g?5 3(ii)] ^ : 3THVrR 39 step 2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as under; P{c) = P(s)*(l+M/100), where P(s) = Average Price to Retailer of the scheduled formulation as calculated in stepl above and M = % Margin to retailer and its value=16

Explanation.- where the scheduled formulation under consideration is coming under more than one subtherapeutic category, the Average Price to Retailer of the scheduled formulation shall be calculated after taking into consideration the percentage reduction in Average Price to Retailer of other schedule formulations under all such sub-therapeutic categories and the lowest average price to retailer shall be taken for calculating the ceiling price of the scheduled formulation under consideration;

(iii) in case the other strengths or dosage forms of the scheduled formulation are not available in the schedule and there is no sub therapeutic category of the scheduled under consideration, the ceiling price shall be calculated as under; Stepl: First the Average Price to Retailer of such scheduled formulation i.e. P(s) shall be calculated as under; P{s) = Pr,{l-{P|i+Pi2+...)/(N*100)} Where, Pn, = Price of highest priced formulation taken for calculating the average price to retailer of the formulation under consideration. Pi = % reduction in Average Price to Retailer of other schedule formulations (calculated as in stepl sub-paragraph (1) of paragraph 4) in same therapeutic category as that of the scheduled formulation under consideration w.r.t the highest priced formulation taken for calculating the average price to retailer. N = Number of such other schedule formulations in same therapeutic category as that of the scheduled formulation under consideration. .Step2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as under; P(c) = P(s).|l+M/100), where P{s) = Average Price to Retailer of the scheduled formulation as calculated in stepl above and M = % Margin to retailer and its■value=16

Explanation.- where the scheduled formulation under consideration is coming under more than one therapeutic category, the Average Price to Retailer of the scheduled formulation shall be calculated after taking into consideration the percentage reduction in Average Price to Retailer of other, schedule formulations under all such therapeutic categories and the lowest average price to retailer shall be taken for calculating the ceiling price of the scheduled formulation under consideration.

(2) Notwithstanding anything contained in this paragraph, where the price has been fixed and notified by the Government under the Drugs (Prices Control) Order, 1995 the provisions of sub-paragraph (1) shall not apply.

7. Margin to retailer.- While fixing a ceiling price of scheduled formulations and retail prices of new drugs, sixteen percent of price to retailer as a margin to retailer shall be allowed.

8. Maximum retail price.- (1) The maximum retail price of scheduled formulations shall be fixed by the manufacture/s on the basis of ceiling price notified by the Government plus local taxes wherever applicable, as under; Maximum Retail Price = Ceiling price + Local Taxes as applicable

(2) The maximum retail price of a new drug shall be fixed by the manufacturers on the basis of retail price determined by the Government plus local taxes wherever applicable, as under; Maximum Retail Price = Retail Price + Local Taxes as applicable

9. Reference data and source of market based data.- (1) Initially, the source of market based data shall be the data available with the pharmaceuticals market data specializing company - IMS Health (IMS) and if the Government deems necessary, it may validate such data by appropriate survey or evaluation.

(2) The Government may in the due course of time come out with other appropriate mechanism of collecting or obtaining the market based data related to drugs and the decision of Government with respect to collection or obtaining of data shall be final.

(3) The market based data, for fixing the ceiling price of scheduled formulations for the first time after the notification of this order, shall be the data of May, 2012. 40 THE GAZETTE OF INDIA : EXTRAQRniNARV ■ [Part II—SEC. 3(ii)] a revision in the first schedule six month of notification of revision in the first under the provisions of the said order, up to 3l“ May 2012 shaii rema Order, 1995, fixed and notified under the provisions of DrSgs (Pricrs t 'i q ̂ remain effective for one year from the date of notification of sulh nr 31 May, 2012, shaii immediately thereafter the manufacturers may-revise the prices as LTfh' ’’"'if' previous calendar year announced by Department of Industrial Promnti^ the annual wholesale price index for the in the First Schedule of this order, fixed'a^d notS unShe p^Sns of the s^ald^ remain effective for further one year i.e. up to the 30‘^Mav'20l rf ' 2012, shall as i„ casp erf „,h„ ran,™ effea.va for one ,aar from ,he data of notification of sTo te quantity in the pack as the case may be. multiplying the same with the number sita for that catego^TmldWn*“fspirflei m“lho 0™“'”jld ‘'''"'“I'' 'I'd ld«»«t thareoddar,-shall ba taken as onit dosage “r calcltm.?^ T "■ “““ »' “«> “1 «>. manufacturer- (1) A ™w”turt" fnXgTSJteT^^^ °! fannehad by a - ceiling price (plus local taxes as applicable so fixed^^ formulations at a price higher than the. formula.,ons doumward no. axca.ding the calling price (plus l«.| tLa/a^rppfabTa)- maximum retail or pack rules case may be, for thatper unit price of even non-scheduled medicines ensure within a period of forty-five davs of thprice of such scheduled formulation does not exceed the c^lL I r f f notification that the

(2) All the existing manufactures of scheduled formuiaf ii- ' ^ local taxes as applicable), scheduled formulations at a price lower than the ceiling price'fplL'kfca^f of Government shall maintain their existing maximum retail priL notified by the ::lSS' '-^;~~™-csr,ledo„.paragraphs (2)''and JsTof'pVayaVh 16." 'IRtl mi ; SWIVTOT 41 thT»?™ltn'of" T °' f the prices shall be madethe provision of sub-paragraph (4) of paragraph 16.

14. Fixation of ceiling price of scheduled formulations.- (1) The Government shall fix and notify the ceiling prices of man f r T f T' 'u provisions of the paragraphs 4 and 6, as the case may be and no so fixedlTn'o^iherblt Go:etnm/:r'"'°" ''' as per Spirable) fixL'"a^"d^no%-^7h\r'r''^''"‘^ formulation at a price higher than the ceiling price (plus local taxesppl.cable) fixed and notified by the Government, such manufacturers shall be liable to deposit the overcharged amount along with interest thereon from the date of such overcharging. ®

15. Fixation of retail price of a new drug for existing manufacturers of scheduled formulations.- (1) The Government 2 rremind m rT- of this order with aView to recommend the retail prices of new drugs on the principles of "Pharmacoeconomics". MidTd„'e'sMrh“""* *“6 ‘<“>8“ ""‘I as specified ip Nationai Ust of EssentialMedicines iaonches a new drug, such existing manufacturers shall apply for prior price approval of such new drug from the Government in Form-I specified under Schedule-ll of this Order. ^

(3) On receipt of the application under sub-paragraph (2), in the event of the new drug available in domestic market the Government shall fix the retail price of the new drug in accordance with the provision of sub-paragraph (1) of to S d " r'" • not available in domestic market, the Government shall forward the sameto the Standing Committee of Experts who shall examine the application on the principles of "Pharmacoeconomics" and Government within thirty days of the receipt of

(4) The Government shall on receipt of recommendation under sub-paragraph (3), within thirty days, fix the retail price of such new drug and such price shall be applicable to such applicant of such new drug.

(5) Where existing manufacturer of scheduled formulation fails to apply for prior approval of the price of the new drug in Form-k such manufacturer shall be liable to deposit the overcharged amount over and above such price fixed and notified by the Government, if any, along with interest thereon from the date of launch of the new drug, in addition to the penalty. as

(6) No existing manufacturer of a scheduled formulation shall sell such , . , a new drug at a price higher than the retail price(p us local taxes as applicable) fixed by the Government for such new drug and In case such a manufacturer is found to ' sell such a new drug at a price higher than the retail price (plus local taxes as applicable) fixed by the Government, such manufacturer of the new drug shall be liable to deposit the overcharged amount along with interest from the date of overcharge, in addition to the penalty. i

16. Revision of ceiling price of scheduled formulations.- (l) The Government shall revise the ceiling prices of scheduled formulations as per the annual wholesale price index (WPI) for preceding calendar year on or before April of every year and notify the same on the l" day of April every year.

(2) The manufacturers may increase the maximum retail price (MRP) of scheduled formulations once in a year, in the month of April, on the basis of the wholesale price index with respect to previous calendar year and no prior approval of the Government in this regard shall be required.

(3) Information about the revision, if carried out, shall be forwarded to the Government iri either electronic or physical form in Form-ll within a period of fifteen days of such revision and non-submission of information under this subparagraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging.

(4) In case of decline in wholesale price index, there shall be a corresponding reduction in the maximum retail price and in case of scheduled formulations produced or available in the market before the date of notification of revised ceiling price, the manufacturers shall ensure within a period of forty-five days of the date of such notification that the maximum retail price (MRP) of such scheduled formulation does not.exceed the revised ceilihg price (plus local taxes c; applicable) and information about the revision shall be sent to the Government in either electronic or physical^orm in Form-ll within a period of fifteen days of such revision. as

(5) Non-submission of information under the sub-paragraph (4) shall be construed as non reduction in maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the maximum retail price revised based on decline in wholesale price index, alongwith interest thereon as overcharged amount from the date of overcharging. /9?g4G//3-6 42 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)] ̂ SMatenffh"'? '' ‘he first schedule, clearly stating the Health and FTrl'ilflharea^^^ Sovernment within slsty days of receipt of communication from the Ministry ofHealth and Family Welfare and the amendment(s) or revision, if required, in the first schedule shall hp nm-ifipH Inri thereafter the celling price|s| for the medici„e(s| added In the first schedule shall be lx as p , he ro.l on of hi order Within a period Of Sixty days from the date Of the notification. per tne provisions of this

(2) The medicines omitted from the first schedule shall fall under the categoty of non-scheduled formulations

18. Rev,s,on of celling price on the basis of moying annual turnover (MATI.- The revision of celling prices of moving annual turnover value shall be carried out,- five years from the'date of^fi'xin'g “hiSrprl^el'^this 0^0^ ̂hictv'lMfeXlf prices (MRP) P«‘l'rd‘r“esJnTdlt tte non'^redS"^^^^ "'“™™ ‘"“I wrTreS:'%at“rof.maximum retail price for next twelve ntont™ " ' ‘he same to the level of ten percent on the basis or or the i~p“SL“:;dti:^:;:'rar^^^ .^e date of availability of scheduled .formu°Lio!lf allf thrSr'phal-maIlltfcTi""'T P^oduc'tion and formulation and the manufacturer of scheduled formulations and thP f contained in the . scheduled .hescheduledformulationshallfurnlshthelnforJrnlraLrn;!^^^^^^ Shall issue a nlli°clllTalsl1nt™eSr^^^^^^^ ^be market SIX month prior to the intended date of discontinuation and tho r " °*^^bis order in this regard at least rrianufacturer of the scheduled formulatl Z^^^^^^^^^ ^i-t the iSatr within a p^eriod^S; j orugsrequire a manufacturer, importer or distributor as the case may bmoost' Government may by notice, . provisions of the Drugs (Prices Control) Order 1979 on or bLr'p^h ^ under thePrices Equalisation Account and the rnalufactuVer im^lrter ^be Drugs .hnoup, i„,„ ,hu suid account within such time us th. Govornmunt muy specify in the Il'd™ to ““ Order, end the umount deposited uIldtoShwgmp^HrsSlbe^^^^^^ f" of this price and the common selling prfce “o^^L^tht wsl^mly^L^^t^^^ T? bis retention poductlon, or seeurtng the equltehle distribution end avellebilty at ..)meed„gtheexpensesincurredbytheGovemmentindlsch,.ingthefunc;ionsund:rthisperugru^,.end ; [tiFi II-Tgw^3(ii)] 43

(c) promoting higher education and research in Pharmaceutical Sciences and Technology and for the purposes incidental thereto.

23. Recovery of overcharged amount under Drugs Prices Control Orders 1987 and 1995.- Notwithstanding anything contained in this order, the Government shall by notice, require the manufacturers, importer.-or distributor or as the case may be, to deposit the amount accrued due to charging of prices higher than those fixed or notified by the Government under the provisions of Drugs (Prices Control) Order, 1987 and Drugs (Prices Control) Order, 1995 under the provisions of this Order.

24. Carrying into effect the price fixed or revised by the Government, its display and proof thereof.- (1) For all the scheduled formulations having maximum retail price (MRP) higher than ceiling price (plus local taxes as applicable), the manufactures shall revise the maximum retail price (MRP) not exceeding the ceiling price (plus local taxes as applicable):

Provided that in case of scheduled formulations produced or available in the market before the date of notification of ceiling price, the manufacturers shall ensure within a period of forty-five days of the date of the notification that the maximum retail price of such scheduled formulation does not exceed the ceiling price (plus local taxes as applicable).

(2) Every manufacturer of a schedule formulation intended for sale shall display in indelible print mark, on the label of container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that formulation based on the ceiling price notified in the Official Gazette or ordered by the Government in this behalf with the words "Maximum Retail Price" preceding it and the words 'inclusive of all taxes' succeeding it.

(3) Every manufacturer shall issue a price list and supplementary price list, if required, in Form V to the dealers. State Drugs Controllers and the Government indicating reference to such price fixation or revision as covered by the order or Gazette notification issued by the Government, from time to time.

(4) Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. -

25. Display of prices of non-scheduled formulations and price list thereof.- (1) Every manufacturer of a non-Scheduled formulation intended for sale shall display in indelible print mark, on the label of container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that formulation with the words "Maximum Retail Price" preceding it and the words 'inclusive of ail taxes' succeeding it.

(2) Every manufacturer shall issue a price list and supplementary price list, if required, of the non-Scheduled formulations in Form-V to the dealers. State Drugs Controllers and the Government indicating changes, from time to time. #

(3) Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer or importer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

26. Control .of sale prices of formulations.- No person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less.

27. Sale of split quantities of formulations.- No dealer shall sell loose quantity of any formulation at a price which exceeds the pro-rata price of the formulation.

28. Manufacturer, distributor or deaier not to refuse sale of drug.- Subject to the provisions of the Drug and Cosmetics Act, 1940 (23 of 1940) and the.rules made thereunder, -

(a) no manufacturer or distributor shall withhold from sale or refuse to sell to a dealer any drug without good and sufficient reasons;

(b) no dealer shall withhold from sale or refuse to sell any drug available with him to a customer intending to purchase such drug.

29. Maintenance of records and production thereof for inspection.- Every manufacturer shall maintain records relating to the sales of individual active pharmaceutical ingredients or bulk drugs manufactured or imported and marketed by him, as the case may be, and the sales of formulations units and packs and also such other records as may be directed from time to time by the Government and the Government shall have the power to call for any record and to inspect such records at the premises of the manufacturer.

30. Power of entry, search and seizure.- (1) Any Gazetted Officer of the Central Government or of ̂'State Government, as the case may be, authorised by a general or special order by the Central Government or by th^ State Government, as 44 . THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)] the case may be, in this behalf may, with a view to securing compliance with this Order or to satisfy himself that the provision of this Order have been complied with-

(a) enter and search any place;

(b) seize any drug, alongwith the containers, packages or coverings in which the drug is found, in respect of which he suspects that any provision of this Order has been, is being, or is about to be contravened, and thereafter take ail measures necessary Tor securing production of the drug, containers, packages or coverings, so seized, in a court of iaw and for their safe custody pending such production;

(c) seize any document, such as, cash memo or credit memo books, books of account and records of purchase and saie of the drugs in respect of which he suspects that any provision of this Order has been, is being, or is about to be contravened.

(2) The provisions of Code of Criminal Procedure, 1973 (2 of 1974), relating to search and seizure shall, so far as may be, apply to searches and seizures under this Order.

31. Power to review.- Any person aggrieved by any notification issued or order made under paragraphs 4, 5 and 6 of this Order, may appiy to the Government for a review of the notification or order within a period of thirty days of the date of publication of the notification in the Officiai Gazette or the receipt of the order by him, as the case triay be, and the Government may make such order on the application as it may deem proper: .

Provided that pending a decision by the Government on the appiication submitted under the above paragraph, no manufacturer shali seil a scheduied formulation or a new drug, as the case may be, at a price exceeding the ceiling price or retail price, as the case may be, fixed by the Government of which a review has been applied for.

32. Non-application of the provisions of this order in certain cases.- The provisions of this order shall not apply to, -

(i) a manufacturer producing a new drug patented under the indian Patent Act, 1970 (39 of 1970) (product patent) and not produced elsewhere, if developed through indigenous Research and Deveiopment, for a period of five years from the date of commencement of its commercial production in the country,

(ii) a manufacturer producing a new drug in the country by a new process deveioped through indigenous Research and Deveiopment and patented under the indian Patent Act, 1970 (39 of 1970) (process patent) for a period of five years from the date of the commencement of its commercial production in the country,

(iii) a manufacturer producing a new drug involving a new delivery system developed through Indigenous Research and Deveiopment for a period of five years from the date of its market approval in india:

Provided that the provision of this paragraph shali apply only when a document showing approval of such drugs from Drugs Controller General (India) is produced before the Government.

Explanation.- Notwithstanding anything contained in this Order, for the purpose of this paragraph "new drug" shall have the same meaning as is assigned to under rule 122E of the Drugs and Cosmetics Rules, 1945. new [File No. 31011/17/2012-PI-ll] SHAMBHU KALLOLIKAR,Jt. Secy.

SCHEDULE-1 . (See Paragraphs-2(t),2(zb)) P. S and T appearing in NLEM 2011 denote essentiality at Primary, Secondary and Tertiary levels respectively. NATIONAL LIST OF ESSENTIAL MEDICINES 201 1 Section: 1 - Anesthesia

1.1 General Anesthetics and Oxygen Medicines Category Route of Administration Strengths Ether S,T Inhalation Halothane with vaporizer S,T Inhalation 45 ie\ InhalationS,TIsoflurane # 10 mg/ml, 50 mg / ml InjectionP, S,TKetamine Hydrochloride InhalationP, S,TNitrous Oxide t InhalationP, S,TOxygen

0.5 g, 1 g powderInjectionS,TThiopentone Sodium Added Medicines InhalationTSevoflurane 1 % oil suspensionInjection . 1.2 Local Anesthetics P,S,TPropofol Route of Administration/ Dosage Form StrengthsCategoryMedicines . 0.25%, 0.5%, 0.5% to be mixed with

7.5% glucose solution Bupivacaine Hydrochloride InjectionS,T 2-5%, . 1-2%, 5% +7.5% Glucose- Topical Forms, Injection, Spinal P, S,TLIgnocaine Hydrochloride 1%, 2% + Adrenaline1:200,000 Lignocaine Hydrochloride + Adrenaline InjectionP, S,T Added Medicines CreamTEM LA cream

1.3 Preoperative Medication and Sedation for Short Term Procedures Route of Administration/ Dosage Form StrengthsCategoryMedicines

0.6 mg / mlInjectionP, S, TAtropine Sulphate 5 mgTablets Injection, Syrup, Suppository 5 mg / ml 2mg/5ml P,S,T Diazepam S,T 5ma 1 mg / ml 5 mg / mlInjectionP, S,TMidazolam 10 mg / mlInjectionS,TMorphine Sulphate Promethazine 5 mg / 5 mlSyrupP, S, T Section: 2 - Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used Gout and Disease Modifying Agents used in Rheumatoid Disordersto treat 7 1-Nnn.nnioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory IVledicines Route of Administration/ Dosage Form _ Tablets Strengths CategoryMedicines 325, 350 mg PAcetyl Salicylic , S, T \ 46 THE GAZETTE OF INDIAr EXTRAORDINARY [Part ll—Sec. 3(ii)] Acid T Tablets 50 mg 25 mg / ml 200 mg, 400 mg 100mg/5ml Diclofenac T Injection Tablets Syrup Ibuprofen P, S, T P, S,T Injection 150 mg/ml P, S,T Syrup Tablets 125 mg/5ml 500 mg Paracetamol P, S,T P, S,T Suppository 2,2 Opioid Analgesics 80 mg, 170 mg Route of Administration/. Dosage Form Medicines Category %Strengths Injection 10 mg/ml ■ Morphine Sulphate S,T Tablets 10 mg Added medicines Injection Cap Injection Tramadol 50 mg/ml 50 mg,100 mg 50ug/ml 2ml ampoule S,T Fentanyl S,T

2.3 Medicines used to treat Gout TabletsAllopurinol S, T 100 mg

0.5 mg Colchicine S,T Tablets

2.4 Disease modifying agents used in Rheumatoid disorders SAzathioprine ,T Tablets 50 mg Methotrexate S,T Tablets 5mg, 7.5mg. lOmq Sulfasalazine S,T Tablets 500 mg Added medicines Hydroxychloroquine phosphate Leflunomide S,T Tablets 200 mg S,T Tablets lOmg, 20 mg tab Section: 3 - Antiailergics and Medicines used in Anaphylaxis Route of Administration/ Dosage Form Injection Medicines Category Strengths Adrenaline Bitartrate Chlorpheniramine Maleate Dexchlorpheniramine Maleate Dexamethasone P, S, T 1 mg / ml P, S,T Tablets Syrup 4 mg P, S, T 0.5 mg/5 ml P, S,T Tablets 0.5 mg Injection 4 mg/mlHydrocortisone Sodium Succinate Pheniramine Maleate~~ Prednisolone P, S,T Injection 100 mg P, S, T P, S, T Injection Tablets

22.75 mg / ml 5 mg, 10 mg, 20 mqPromethazine P, S,T Tablets 10 mg, 25 mg 5 mg / 5 mlSyrup Added Medicines Cetrizine P,S,T Tablets Syrup lOmg 5 mg/ml Section: 4 - Antidotes and Other Substances used in Poisonings 4

4.1: Nonspecific Route of Administration/ Dosage Form Oral Medicines Activated Charcoal Category Strengths P,S,T

4.2: Specific Medicines I Category Route of Administration/ Strengths 47[«mi 11-^005 3(ii)] ^Tti : 3rei<'3R?I Dosage Form 1 mg/mlInjection Injection Polyvalent Solution/ Lyophilyzed Polyvalent Serum P,S,TAtropine Sulphate Specific Antisnake venom P,S,T 4 100 mg/mlInjection Injection P.S.TCalcium gluconate 500 mgS,TDesferrioxamine mesylate 10 nig / mlInjection■ t S,TMethylthioninium chloride (Methylene blue) Penicillamine 250 mgTablets or CapsulesS,T 50 mg / ml

0.1 mg / ml Injection in oilS,TDimercaprol InjectionTFlumazenil 30 mg / mlInjection Injection S,TSodium Nitrite 250 mg/ ml

0.4mg/ml 25 mg/mt S,TSodium Thiosulphate InjectionP,S,TNaloxone InjectionP,S,TPralidoxime Chloride(2- PAM] Added medicines: 200 mg/ml(5 ml) ,P.S.T 1 InjectionN-acetylcysteine Section: 5 - Anticonvulsants/ Antiepileptics Route of Administration/ Dosage Form StrengthsCategoryMedicines lOOmg 200mg 100 mg/5mr 5 mg /ml Tablets. P, S,TCarbamazepine Syrup InjectionP,S,TDiazepam 500 mg /mlInjectionS,TMagnesium sulphate 30 mg, 60 mg 200 mg/ml 20 mg/5ml TabletsP,S,TPhenobarbitone Injection Syrup ST P.S.T P.S.T 50 mg, lOOmg 25mg/ml 50 mg/ml Capsules or Tablets Syrup Injection Phenytoin Sodium 200 mg, 500mg 200 mg/5ml Tablets Syrup P.S.TSodium Valproate 100 mg/mlInjectionT Added Medicines 2m9/mlInjectionTLorazepam Section: 6 - Anti-infective Mcilicincs

6.1 Anthelminthics

6.1.1 Intestinal Anthelminthics Route of Administration/ Dosage Form StrengthsCategoryMedicines 400 mg 200 mg/ 5 ml Tablets Suspension P.S.TAlbendazole Added Medicines

4.5 gm 750mg/5ml Tablets Solution P.S.TPiperazine

6.1.2 Antifilarials Route of Administration/ Dosage Form Strengths CategoryMedicines 50 mgTabletsDiethvicarbamazine citrate P.S.T ^ ^ ^ 613 Antlschlstosomals and Antitrematode Medicines Route of Administration/ |CategoryMedicines Strengths t 48 THE GAZETTE OF INDIA : EXTRAORDINAR v [Part 11—Sec. 3(ii)i Dosage Form Tablets Praziquantel S, T 600 mg

6.2 Antibacterials _6.2.1 Beta lactam medicineg Route of Administration/ Dosage Form Powder for suspension Capsules • Capsules Powder for suspension Injection Category S,T P Medicines » Strengths 125 mg / 5 ml 250 mg. 500 mo 250 mg, 500 mg 125 mg / 5 ml 500 mg Amoxicillin Ampicillin ,S,T Benzathine' Benzylpenicillin Cefotaxime P.S.T ' Injection 6 lacs, 12 lacs units 125 mg, 250 mg 500 mp 250mg. 1g 250 mg. 1 g 125 mg/5 ml 250 mg. 500 mg 250 mg, 500 mg 250 mg 125mq/ 5 ml S, T ■ Injection Ceftazidime Ceftriaxone Cephalexin S, T Injection Injection Syrup Capsules Capsules Injection Liquid S, T P,S,T Cloxacillin P,S,T Added Medicines Amoxicillin+Clavulinic acid T Tablets Powder for suspension Injection Tablet

6.2.2 Other antibacteriak Route of Administration/ Dosage Form Injection Tablets Suspension Injection Injection Tablets Tablets T S,T S,T P,S,T P,S,T 625 mg

228.5mg/5ml 600mg. 1.2om

100. 200mo Cefixime Medicines Category StrengthsAmikacin 250 mg/2 ml 100, 250,500mg 100mg/5ml 500mq 200 mg /100 ml ■ 250 mg, 500 mn 80 + 400 mg 160+800 mg 40 + 200 mg / 5 Azithromycin Ciprofloxacin Hydrochloride C6-Trimoxazole (Trimethoprim + Sulphamethoxazole) Suspension Doxycyciine Erythromycin Estolate mlP,S,T Tablets Syrup Tablets Injection 100 mg 125 mg/5 ml 250 mg, 500 mg 10 mg/ml, 40 mg/ml 200mg,400m g 500mg/100ml _ 100mg/5ml 100 mg 500 mg 500 mg, 1 q P,S,T Gentamicin P,S,T Metronidazole P,S,T Tablet Injection Syrup Tablets Tablets Nitrofurantoin Sulphadiazine Vancomycin Hydrochloride P,S,T S, T T Injection rosy medicinna Route of Administration/ Dosage Form Capsules

6.2.3 Antilei CategoryMedicines Strengths 50 mg. 100 mg 50 mg, 100mq --'Q rng. 300 me15 Ciofazimine Dapsone Rifampicin P^T Tabfets bT^’LL.J——Caps^jteT^Frghj^P-Z.4 Antituberculosia mnriirin,. Category ~ P.S.T Route of AdministrationMedicines EthambutoT / Dosage Form Tabiets Strengths 200 mg. 40q7[^ 49wra ̂ TOT5 : areii-wil[tun II--!3ir5 3(ii)] #-■ 600 mg, 800 mg 50 mg, 100 mg, 300 mg 100 mg/5ml Tablets Syrup Tablets Syrup P,S,TIsoniazid 100 mg, 200 mg 50 mg / 5 ml 500 mg, 750 mg, 1000 mg, 1500 * S,T.Ofloxacin Tablets mgP,S,TPyrazinamide 50 mg, 150 mg, 300 mg,450 mg 100 mg/5 ml Capsules/Tablets- SyrupP,S,TRifampicin . Streptomycin Sulphate 0-75 g, 1 gInjection- ~P:SJ

6.3 Antifungal medicines . Route of Administration/ Dosage FormCategory StrengthsMedicines 50 mgInjection Pessaries S,TAmphotericin B 100 mg, 200 mg. 2%GelP,S,TClotrimazole 50 mg, 100 mg, 150 mg, 200 mg 125 mg, 250 mg Fluconazole Capsules or TabletsS,T Capsules or TabletsP,S,TGriseofulyin 500,000 lU 100,000 lU Tablets PessariesP,S,T ,Nystatin

6.4 Antiviral medicines

6.4.1 Antiherpes medicines Route of Administration/ Dosage Form Tablets' Category StrengthsMedicines 200 mg, 400 mg 250 mg, 500 mg 400 mg / 5 ml S,TAcyclovir Injection Suspension

6.4.2 Antiretroviral medicines

6.4.2.1. Nucleoside reverse transcriptase inhibitors Route of Administration/ Dosage FormCategory Strengths Medicines 250 mg, 400 mg 150 mg 150 mg+ 200 mg+ 30 mg ■■ 150 mg + 300 TabletsS,TDidanosine TabletsS,TLamivudine Lamivudine + Nevirapine + y'" Stavudine TabletsS,T Lamivudine + Zidovudine maTabletsS,T 15 mg, 30 mg, 40 mg 100 mg, 300 CapsulesS,TStavudine mgTabletsS,TZidovudine ADDED MEDICINES 30mg+ 150mgTabletsS,TStavudine+ Lamivudine ■ 300mg+ 150mg+ 200mg TabletsZidovudine+ Lamivudine+ Nevirapine 4

6.4.2.2 Mnn.niicleoside reverse transcriptase inhibitor i Route of Administration/ Dosage Form StrengthsCategoryMedicines 200 mg, 600 mgCapsules■ S,TEfavirenz . 200 mg 50 mg / 5 ml Capsules SuspensionS.TNevirapine

6.4:2.3 Protease inhibitors Route of Administration/ Dosage Form Capsules Category S Strengths 200 mg, Medicines ,TIndinavir 50 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(ii)1 Nelfinavir S.T Capsules 250 mg 100 mg,Capsules Syrup ■ Ritonavir S,T 400 mg / 5miSaquinavir S,T Capsules

6.5 Antiprotozoal Medicinea 6j.1 Antlamoebic and Antigiardlasls medlr.lnna Route of Administration/ Dosage Form Category 200 mg '¥■ Medicines Strengths Diloxanide Furoate P.S.T Tablets 500 mg 200 mg, 400 mg 500 mg /IQQ ml Metronidazole P,S,T Tablets Injection

6.5.2 Antileishmaniasis medicines Route of Administration/ Dosage Form CategoryMedicines Strengths Amphotericin B S,T injection Injection 50 mgPentamidine isothionate Sodium Stibogluconate S,T 200 mg 100 mg/ml S,T Injection

6.5.3 Antimalarial Medicinea

6.5.3.1 For curative treatment Route of Administration/ Dosage Form CategoryMedicines Aftesunate (To be used only in combination with Sulfadoxine +Pyrimethamine) Strengths P,S,T Tablets 50 mg Tablets Injection Syrup Chloroquine phosphate 150 mg base 40 mg / ml 50 mg / 5 ml

2.5 mg. 7,5 mg 25 mg 300 mg 300 mg / ml P,S,T Primaquine Pyrimethamine Quinine sulphate Sulfadoxine + Pyrimethamine P,S,T Tablets TabletsP,S,T P,S,T Tablets InjectionST P,S,T Tablets 500 mg + 25 mg Medicines addedClindamycin Tablet 150, 300mg6.5.3.2 For prophylaxis Category Route of AdmMedicines inistration/ Dosage Form Strengths Medicines added Mefloquine S,T Tablet T 250 mg base ^ Antipli^mocystosl^m[JArnito^i;j^^ ___JW^dicines Category Co-Trimoxazole p s j (Trimethoprim + Sulphamethoxazole) Pentamidine Isothionate Route of Administrat Suspension S I medicinesion/ Dosage Form Tablets Strengths 80 + 400 mg. 160+800 mg 40 + 200 mg/5 .'i. ml,T njection 200 mg Section: 7-Antimigraine medicines

7.1: For treatment of aciitn attack Category Route of AdministraMedicines Acetyl Salicylic Acid Dihydroerqotamins Paracetamol tion/ Dosage Form L Tablets Strengths P,S,T 300 - 350 moS, T Tablets -—J Tablets

7.2: For Prophylaxis Route of Administration/ Dosage Form -Tablets 1 mgP,S,T 500 mg Medicines Propranolol hydrochloride Category Strengths ^Omg, 40 mgP,S,T. ,[»nnll-w3(ii)] 51 Section: 8 - Antineoplastic, immunosuppressives and medicines used in palliative care

8.1: Immunosuppressive medicines Route of Administration/ StrengthsMedicines Category Dosage Form Tablets 50 mgAzathioprine Cyclosporine T 10 mg, 25 mg, 50 mg, 100 mg T Capsulest Concentrate for Injection 100 mg/ml

8.2: Cytotoxic medicines Route of Administration/ StrengthsMedicines Category Dosage Form

0.5 mgInjectionActinomycin D Alpha Interferon Bleomycin Busulphan Cisplatin T 3 million lUInjectionT 15 mgInjectionT Tablets 2 mgT 10 mg/vial 50 mg / vial InjectionT 50 mg, 200 mg 500 mg Tablets InjectionTCyclophosphamide 100 mg/vial 500 mg/vial 1000 mg/vial Cytosine arabinoside InjectionT Capsules ' Injection 50 mg, 100 mgTDanazol 10 mg, 50 mg•T. Doxorubicin 100 mg 100 mg/ 5 ml vial Capsules InjectionTEtoposide 250 mg 250 mg / 5 ml TabletTFlutamide InjectionT5-Fluorouracil 3 mg/ml 200 mg InjectionTFolinic Acid " Gemcita.bine hydrochloride L- Asparaginase InjectionT . Igm 5000 KU.InjectionT 2 mg, 5 mgTabletTMelphalari 50 mg 100 mg/ml Tablet InjectionTMercaptopurine

2.5 mg 50 mg / ml Tablet InjectionTMethotrexate 10 mgInjection Injection Mitomycin-C 30 mg / 5 ml 50 mg V Paclitaxel CapsulesTProcarbazine Vinblastine 10 mgInjectionT sulphate 1 mg / mlInjectionT-Vincristine* Added medicines 150 mg, 450 mgInjectionTCarboplatin vial 500 mg 20 mg vial 1 gm/2ml vial Injection Injection Injection TDacarbazine TDaunorubicin TIfosfamide 200 mgInjection Injection Tablets TMesna 50 mg vial TOxaliplatin 100 mg, 400 mg TImatinib 52 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)1 (P- Chlorambucil | T Tablats 2 mg

8.3; Hormones and antihormonaa Route of Administration/ Dosage Form Medicines Category . Strengths Tablets 5 mg V Prednisolone S,T 20 mg, 25 mg (as sodium phosphate or succinate) 60 mg 10 mg, 20 mg Injection Raloxifene Tablets .Tamoxifen Qtrate T Tablets

8.4: Medicines used in palliative care Route of Administration/ Dosage Form CategoryMedicines Strengths Morphine Sulphate T Tablets 10 mg Tablets 4 mg, 8 mg Ondansetron S,T Injection 2 mg/ml Syrup 2 mg/5 ml Added Medicines Filgrastim Injection Tablets 1 ml vial ■ 100 mg ■ Allopurinol T Section: 9 -Antiparkinsonism medicines Route of Administration/ Dosage Form Medicines Category Strengths Bromocriptine Mesylate S,T Tablets 1.25 mg, 2.5 mg Levodopa+ Carbidopa P,S,T Tablets 100 mg+10 mg 250 mg+25 mg 100 mg+25 mg ■2 mg Trihexyphenidyl Hydrochloride P,S,T Tablets Section: 10 -Medicines affecting the blood

10.1: Antianaemia medicines Route of Administration/ Dosage Form Medicines Category Strengths Cyanocobalamin. P, S,T Injection 1 mg/ml. Ferrous Sulphate/ Fumrate P,S,T Tablets Tablets equivalent to 60 mg elemental iron 25mg elemental iron (as sulphate)/ml 1 mg;5mg 50 mg iron/ml 10 mg Oral solution Folic Acid P,S,T ' Tablets Iron Dextfan S,T Injection Pyridoxine P,S,T Tablets

10.2: Medicines affecting coagulation Route of Administration/ Dosage Form Medicines Category Strengths Heparin Sodium S, T 1000lU/ml 5000lU/ ml Injection Protamine Sulphate S, T Injection 10 mg/rril Phytomenadione Warfarin sodium P, S, T Injection 10 mg/mlS, T Tablets 5 mg Added Medicines Enoxaparin T Injection 40mg, 60ma 53i^Ra ̂ wra : 3TOI*OT[ilFI 3(ii)] Section: 11 -Blood products and Plasma substitutes 11,1: Plasma Substitutes Route of Administration/ StrengthsCategoryMedicines Dosage Form Inlection 10%P,S,TDextran-40 6%InjectionP,S,TDextran-70 Fresh frozen plasma ■ Hydroxyethyl Starch (Hetastarch) Polygeline InjectionT ( 6%InjectionS, T

3.5%Injection H ■}-. Plasma fractions for specific use Route of Administration/ Dosage Form S,T StrengthsCategoryMedicines 5%, 20 %Injection Injection S,TAlbumin S, T ■Crvoprecipitate Factor VIII Concentrate DriedInjectionS.T Factor IX Complex (Coagulation Factors II,VII, IX, DriedInjectionS,T Platelet Rich Plasma InjectionS,T Section: 12 -Cardiovascular medicines

12.1: Antianoinal medicines Route of Administration/ Dosage Form StrengthsCategoryMedicines 75rTig, lOOmg, 350 mg soluble/dispersible 30 mg, 60 mg Acetyl salicylic acid TabletsP,S,T TabletsS,TDiltiazem 0.5 mg 5mg/ml Sublingual Tablets Injection P,S,T-Glyceryl Trinitrate 10 mg, 20 mg Isosorbide 5 Mononitrate/ Dinitrate TabletsP.S,T 25 rfig; 50 mg ^ 1 mg/ml Tablets InjectionP.S,TMetoprolol Added Medicines 75 mgTabletsTClopidogrel

12.2: Antiarrhvthmlc medicines Route of Administration/ Dosage Form StrengthsCategoryMedicines 3 mg/mlInjectionS,TAdenosine 100 mg, 200 mg 50 mg/ml (3 ml annpoule) Tablets Injection S,TAmiodarone Tablets 30 mg, 60 mgS,T Diltiazem a 5 mg/ mlT Injection 10 mg / ml TEsmolol Injection 1%, 2%InjectionS,TLignocaine Hydrochloride Procainamide 250 mg lOOmg/ml Tablets InjectionTHydrochloride Verapamil I 40 mg, 80 mgTablets 54 THE GAZETTE OF INDIA : EXTRAORniNARv [Part 11—Sec. 3(ii)i L Injection

12.3: Antihypertensive medicines Route of Administration/ Dosage Form

2.5mg/ml Medicines Category Strengths Amiqdipine P,S,T 2.5 mg, -5.^9: Tablets « Atenolol P,S,T . 50 mgTablets Enalapril Maleate Losartan Potassium Methyldopa 100 mo

2.5 mg, 5mg

1.25mq/ml P,S,T Tablets Injection Tablets T S.T 25 mg, 50 mgP,S,T Tablets Capsules Tablets Sustained release tablets or capsules injection 250 mg Nifedipine 5 mg, lOmg 10mg, 20mg 10mg, 20mg S,T Sodium Nitroprusside T 50 mg/ 5 ml Added Medicines Hydrochlorthiazide P,S,T 12.5,Tablets 25 mg

12.4: Medicines used in heart faihiTr Route of Administration/ Dosage Form ^ Tablets Injection Elixir S,T Medicines Category StrengthsDigoxin 0,25 mg

0.25 mg/ml

0.05 mq/mlDobutamine Dopamine Hydrochloride S, T Injection 50 mg / mlS.T Injection 40 mg / ml j2.S: Antithrombotic mnriirinps Route of Administration/ Dosage Form Medicines Category Strengths Acetyl salicylic 75mg, lOOmg, 350 mg soluble/dispersihip P.S.Tacid Tablets S,T InjectionHeparin Sodium 1000 lU/ml 5000 lU/ml S, TStreptokinase Injection 750,000 lU 15,00,000 lUT InjectionUrokinase . 500,000 lU/ml

10.00.000 lU/mlNew uategorv - ADnpn

12.6 Hypoiipidemir. 1 Tablets Atorvastatin P.S.T 5 mg, 10 mg ' Section: 13 -Dirmatological medicines (Topical)

13.1: Aniitunqal medicinp« Route of Administration/ Dosage Form _—Ointment or Cream

13.2: Antiinfective medicines ' Route of Administration/ Dosage Form Medicines Category StrengthsMiconazole P.S.T 2% Medicines Acyclovir Framycetin Sulphate Methyirosanilinium Chloride (Gentian Category Strengths S.T Cream 5% P.S.T Cream

0.5% P.S.T Aqueous solution

0.5%

55.llRti ̂ TTTO ; 3TO1VCT[W II-Tgng 3(ii)] Violet) Neomycin + Bacitracin 5mg + 500IU/gOintmentP.S.T 5%. Solution or OintmentP,S,TPovidone Iodine Silver, Sulphadiazine 1%CreamP,S,T * 13,3: Antiinflammatory and antipruritic medicines Route of Administration/ Dosage Form Category StrengthsMedicines Betamethasone Dipropionate Calamine

0.05%Cream / OintmentP,S,Tt LotionP,S,T

13.4: Astringent Medicines Route of Administration/ StrengthsMedicines Category Dosage Form Dusting PowderZinc Oxide P,S.T

13.5: Medicines affecting skin differentiation and proiiferation Route of Administration/ StrengthsCategoryMedicines Dosage Form 5%SolutionP,S,TCoal Tar Ointment 0.1-2%TDithranol ■ SolutionP,S,TGlycerin Salicylic Acid Solution 5%P,S,T

13.6: Scabicides and Pediculicides Route of Administration/ StrengthsCategoryMedicines Dosage Form 25 %LotionP,S,TBenzyl benzoate Added Medicines 5%Cream Lotion Permethrin S,T 1%, 5% Section: 14 -Diagnostic agents

14.1: Ophthalmic medicines Route of Administration/ StrengthsCategoryMedicines Dosage Form 1%Eye drops Eye Drops S,TFluorescein 4%S.TLignocaine Tropicamide 1%Eye drops

14.2: Radiocontrast media S,T Route of Administration/ Dosage Form StrengthsCategoryMedicines 100% w/v, 250% SuspensionS,TBarium Sulphate w/v InjectionS,TCalcium Ipodate 500 mgTabletsS,Tlopanoic Acid 60% w/v (iodine =280 mg / ml) Meglumine lothalamate InjectionS,T 5-8 g iodine in 100- 250 ml Meglumine lotroxate SolutionS,T 500-600 mg / mlOily, suspensionPropyliodone Sodium lothalamate 70% w/v{lodine =420 mg / ml) InjectionS,T 60% w/v(lodine cone. *292 mg / ml), 76% w/v(lodine cone. =370 mg / ml) Sodium Meglumine Diatrizoate InjectionS.T f Section: 15 -Disinfectants and antiseptics

15.1: Antiseptics Route of Administration/ Dosage Form StrengthsCategoryMedicines' SolutionP. S.TAcriflavInr-GIvcerin 56 THE GAZETTE OF INDIA : EXTRAORDINARY [PART U—Sec. 3(ii)] Benzoin Compound P^T Tincture 20% (cone, for dilutioni 5% (cone, for dilution) Cetrimide P,S,T Solution Chlorhexidine P, S,T Solution Ethyl Alcohol 70% P, S.T Solution f

0.5%,Gentian Violet P, S,T Paint 1% Hydrogen Peroxide P, S,T P, S,T Solution 6% Povidone Iodine Solution 5%, 10%

15.2: Disinfectants Route of Administration/ Dosage Form Medicines Category Strengths Contains not less than 30 % w/w of. available chlorine (as per I.P) Dilute 34 ml of formaldehyde solution with water to produce 100 ml (As per I.P) Bleaching Powder P, S, T Powder Formaldehyde Solution • P, S,T Solution Glutaraldehyde S,T Solution ' 2% Potassium P, S,T ‘ Crystals for solutionPermanganate Section: 16-Diuretics Route of Administration/ Dosage Form Medicines Category Strengths Injection Tablets 10 mg/ml 40mg 25 mg, 50 mg Furosemide P,S,T Hydrochlorothiazide P,S,T Tablets Mannitol P,S,T Injection 10%, 20% Spironolactone P,S,T Tablets 25 mg Section: 17 - Gastrointestinal medicines

17.1: Antacids and other Antiulcer medicines Route of Administration/ Dosage Form Medicines Category Strengths Aluminium Hydroxide • + Magnesium Hydroxide Tablet Suspension ' P,S,T ■ Omeprazole P,S,T P.S,T Capsules 10 mg, 20 mg, 40 mo 25 mg / mlRanitidine Injection Added Medicines Pantoprazole Injection Tablets 40 mg Famotidine P,S,T- 20 mg

17.2: Antiemetics Route of Administration/ Dosage Form Tablets Syrup Tablets Syrup . Injection Medicines Category Strengths Domperidone 10 mg 1 mg / ml 10 mg 5 mg / 5 ml 5 mg / ml P,S,T Metoclopramide P,S,T 57 [»tPTlI-W3(ii)] 10 mg, 25 mg 5 mg /5 ml 25 mg / ml Tablets Elixir or Syrup Injection P.S.TPromethazine Added Madicines ■». 4mg, 8 mg 2 mg/ml 2mg/rftl Tablet Syrup Injection Ondansetron S,T

17.3: Antiinflammatory Medicines I Route of Administration/ Dosage Form Added Medicines StrengthsCategoryMedicines 400mg5-Amino salicylic Acid (5-ASA) TabletsS,T

17.4: Antispasmodic medicines Route of Administration/ Dosage Form StrengthsCategoryMedicines 10 mg 10 mg / ml TabletsDicyclomine Hydrochloride Hyoscine Butyl . Bromide P,S,T Injection Tablets Injection 10 mg 20 mg / mlP,S,T •

17.5: Laxatives Route of Administration/ Dosage Form ~ Tablets, Suppository StrengthsCategoryMedicines P.S.T P,S,T

17.6: Medicines used in diarrhorea

17.6.1 Orai dehydration salts Route of Administration/ Dosage Form Granules Bisacodyl ispaghula Strengths CategoryMedicines Glucose; 13.5 g/L Sodium chlcric'e 2.6 g/L Potassium chloriue:

1.5 g/L Trisodlum citrate dihydrate+: 2.9 g/L Powder for dilution in 200ml; 500 ml; . 1000ml. (As per I.P) Powder for solutionOral Rehydration Salts P,S,T

17.6.2 Antidiarrhoeal medicines Route of Administration/ Dosage Form Strengths CategoryMedicines Medicines added 20 mg/5mlSyrupP,S,T^inc Sulfate■ c Section: 18 -HennoneS, other endocrine medicines and contraceptives • Adrenal hormones and synthetic substitut^ Route of Administration/ Dosage Form

18.1 Category Strengths Medicines

0.5mg 4mg/ml Tablets S,T InjectionDexamethasone Hydrocortisone Sodium Succinate . 100 mg/ml‘I InjectionP, S,T L • '--i 58 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—sec. 3(ii)l 'ii I I. ^Methyl Prednisninno S,T Injection 40 mg/ ml Prednisolone 5mo,P, S,T Tablets 10mg, 20m18.2: Andn lens Medicines Route of Administration/ Dosage Form Category Strengths ■» 40mg(as undecanoate) I 25mg/ml(as propionate) Testosterone Capsules Injection P.S.T

16.3: Contraceptives hormonal Contraceptives Route of Administration/ Dosage Form Tablets

18.3.1: Medicines Category Strengths

0.03 mg +0.15 Ethinylestradiol + Levonoroesternl Ethinylestradiol + Norethisterone Hormone Releasing lU P,S,T mg P,S,T ' Tablets 0.035 mg+1.0 mg TD Levonorgesterol Releasing

18.3.2: intrauterine devices Route of Administration/ Dosage Form lUD Medicines lUD containing Copper Category Strengths P,S,T

18.3.3: Barrier Route of Administration/ Dosage Form Medicines Category StrengthsCondoms P,S,T

18..4: testrogens ' RouU of Administration/ Dosage Form Medicines Category Strengths Ethinylestradiol P,S,T O.OImg

0.05m.q Tablets Category Route of Administration/ Dosage Form Medicines Strengths Glibenclamide ” insulin Injection (Soluble) Intermediate Acting(Lente/NPH InsulinI P,S,T Tablets 2.5 mg, 5mg P,S,T Injection 40IU/ml P.S.T Injection 40IU/ml Metformin P.S.T Tablets SOOmg Added medicinogPremix Insulin'30;70 injection P,S,T

18.5.2 Medicines u.seri Category , , injection 40IU/ml ^gi!:gglhypoglvcemmRoute of Administration/ Dosage Form Injection Medicines StrengthsGlucagon T 1 mg/mlAdded medicinp^25% Dextro.se P.S.T —■ Injection Igj-Qyolationh^di]^ 100 ml Medicines Route of Administration/ Dosage Form Category Strengths 59^ fqm Il~®ws3(ii)] gn TTTO : 3raiTO 50mg, 100mg TabletsClomiphene citrate T

18.7 Progestogens Route of Administration/ Dosage Form Tablets i Medicines Category Strengths 5mg, lOmg Medroxy Progesterone Acetate Norethisterone P.S.T TabletsP,S,T 5mg

18.8 Thyroid and antithyroid medicines Route of Administration / Dosage Form Category StrengthsMedicines 5mg,■P.S.T TabletsCarbimazole 10mg 50pg,Levothyroxine P,S,T Tablets 100 Solution 8 mg / 5 mliodine S,T Section: 19 Imtnunoloeicak

19.1: Diagnostic agents Route of Administration/Category StrengthsDrugs Dosage Form Tuberculin, Purified Protein derivative Injection 1 TU, 5 TUP,S,T

19.2: Sera and immunoglobins Route of Administration/ Dosage Form StrengthsCategoryDrugs Anti-D immunoglobin (human) Injection 300 pgS, T Polyvalent Antisnake ■ Venom InjectionP,S,T . 10 ml Antitetanus Human' immunoglobin Injection 250lU,500 lUP,S,T I; * • Diphtheria Antitoxin 10,000 lUs, T t \ Injection Rabies immunoglobin ’ e mlP,S,T Injection

19.3: Vaccines'i’

19.3.1: For Universal Immunisation Route of Administration/ . ' Dosage Form StrengthsCategory ;Drugs * InjectionP^T -* B.C';G Vaccine InjectionD.P.T Vaccine P,S,T Hepatitis‘B ' Vaccine InjectionP,S,TA > f ■ ■ I InjectionP,S,T .IMeasles Vaccine ■ i?Oral.Poliomyelitis vaccine (i-A) SolutionP,S,T j

19.3.2: For Specific Group of Individuats Route of Administration/ Strengths I CategoryDrugs Dosage Form T InjectionP,S,TRabies Vaccine InjectionP.S.TTetanus Toxoid 60 THE GAZETTE OF INDIA : EXTRAORDINARY [PARTlI-^SEC.-3(ii)]0 A. •Section; 20 - Muscle Relaxants (Peripherally acting) and Cholinesterase Inhibitors T-i '1 Route of Administration/ Dosage Form T Drugs Category Strengths Atracurium besylate S,T Injection 10 mg Ami, ■ Tablets,' Injection '♦ ■Neostigmine 15 mg,

0.5mq/ml ' S,T Tablets, Injection Pyridostigmine 60 mg, 1 mg/ml S,T Succinyl choline chloride S,T Injection 50 rng/ml Added drugs • Vecuronium P,S,T Injection 2 mg/ml Section; 21 - Ophthalmological Preparations

21.1: Anti-infective agents Route of Administration/ Dosage Form Medicines Category Strengths Chlorampheni ■■P,S,T Drops/Ointmentcol 0.4%, .1% Ciprofloxacin Hydrochloride P,S,T Drops/Ointment 0.3% Gentamicin P,S,T P,S,T Drops Drops

0.3%Miconazole Povidone Iodine 1%. S,T . Drops 0.6% Sulphaceta mide Sodium P,S,T Drops 10%,20%

21.2: Antiinflammaory agents Route of Administration/ Dosage Form Medicines Category Strengths ' Prednisolone Acetate P,S,T ■ 4,Drops 0.1% •' Prednisolone Sodium Phosphate K.P,S,T Drops 1%

21.3: Local Anaesthetics Route of Administration/ Dosage ^rm Medicines Category Strengths Tetracaine Hydrochloride P,S.T Drops 0.5%

21.4: MIotics and Antiqlucoma medlclnna Category Route of Administration/ Dosage Form Medicines Strengths Acetazolamide S,T Tablets 250 mg

0.25%, Betaxolol Hydrochloride T Drops

0..5% Pilocarpine S,T 2%,Drops y 4%'Timolol P, S.T 0.25%,Maleate Drops

0.5%.21.5: Mydriatics Route of Administration/ Dosage Fofm Medicines Cat^ory Strengths Atropine Sulphate HomatfODine Phenylephrine P.S.T Drops/Ointment 1%. ■/' Drops 2%.>P.8,T L Drops 5%:,; T' 6 l:« 61[WT Il-^3(ii)] ma an Traaa : arai’wn /

21.6; Ophthalmic Surgical Aids Route of Administration/ Dosage Form Medicines Category Strengths Methyl Cellulose 'i T Injection' 2% Section: 22 - Oxytocics and Antioxytocics

22.1: Oxytocics Route of Administration/ Dosage Form Medicines Category Strengths Methyl Ergometrine Tablets Injection

0.125mg

0.2mg/ml P,S,T Mifepristone T Tablets 200mg1 > 5IU/ml, lOlU/ml Oxytocin S,T Injection Added medicines Misoprostol T Tablets lOOug

22.2: Antioxytocics Route of Administration/ StrengthsMedicines Category Dosage Form Terbutaline Sulphate Tablets ! Injection

2.5 mg.

0.5 mg/ml S,T Added Medicines Tablets 10 mgS,TNifedipine Betamethasone Injection 4 mg/mlP,S,T Section: 23 - Peritoneal Dialysis Solution- Route of Administration/ Dosage Form StrengthsCategoryMedicines 40f approximate composition Intraperitoneal Dialysis Solution- T Section: 24 - Psychotherapeutic Medicines - ♦ 24.1: Medicines used in Psychotic Disorders Route of Administration/ StrengthsMedicines Category Dosage Form 25 nig, 50mg, lOOmg 25mg/5ml 25mg/ml Smg/ml Tablets Syrup Injection Chlorpromazine hydrochloride i P.S.T InjectionS,THaloperidol Added medicines 5mq,10mgTabletsTOlanzapine

24.2: Medicines used in mood disorders

24.2.1: Medicines used in Depressive disorders Route of Administration/ Dosage Form StrengthsCategoryMedicines 25 mgTabletsP*SiT PJX- Amitriptyline 20 mgCapsulesFluoxetine 62 THE GAZETTE OF INDIA : EXTRAORDINARY [Part ll—Sec. 3(ii)] hydrochloride Imipramine P.S.T Tablets 25 mg, 75 mg

24.2.2: Medicines used in Bipolar disorders Route of Administration/ Dosage Form Medicines Category Strengths i Lithium Carbonate T Tablets 300 mg Added Medicines 200 mg, 500mg Sodium, Valproate TabletsP.S.T

24.3: Medicines used for Generalized Anxiety and Sleep Disorders Route of Administration/ Dosage Form Tablets Category Str

0.2p.s,r Medicines engths 5 mg,

0.5 mg Alprazolam 2 mg, 5mg

24.4: Medicines used for obsessive compulsive disorders and panic attacks Route of Administration/ Dosage Form P,S,T Tabiets Category Strength Diazepam Medicines s Added Medicines Fluoxetine hydrochloride P.S.T Capsules 20 mg Section: 25 - Medicines acting on the respiratory tract

25.1: Antiasthmatic medicines Route of Administration/ Dosage Form Medicines StrengthCategory 50 pg, 250pg/do . Beclomethasone Dipropionate P,S,T Irihaiation se Hydrocortisone sodium succinate 100 mg, 200mg, 400 mg 2mg, 4mg 2mg/5ml lOOpg/do P,S,T Injection Tablets Syrup Inhalation Saibutamol sulphate P,S,T se Added Medicines Ipratropium bromide ■ 20pg/met ered dose P,S,T inhalation

25.2: Antitussives Route of Administration/ Dosage Form Medicines StrengthCategory s lOmgCodeine phosphate Tabiets Syrup S,T 15mg/ 5ml Dextromethorphan P,S,T Tabiets 30mg Section: 26 - Solutions correcting water, electrolyte and acid-base disturbances i

26.1: Oral Route of Administration/ Dosage Form Medicines Category Strengths Oral Rehydration P, S, T Powder for Solution As per IPSalts

26.2: Parenteral Route of Administration/ Dosage Form Medicines Category Strengths 5% isotonic, 10% 15%. Glucose P, S.T Injection Glucose with sodium chloride P, S, T Injection 5% + 0.9% 63 TO ̂ Wra : TOVIFI[SPlIl-T3nS3(ii)] ^<1

0.9%Injection -P, S, TNormal Saline InjectionS,TN/2 Saline InjectionS.TN/5 Saline Potassium Chloride

11.2% Sol.InjectionP.S.T As per IPInjection .P, S,TRinger Lactate i Sodium As per IPInjectionP, S,T Bicarbonate

26.3: Miscellaneous Route of Administration/ Dosage Form StrengthsCategoryMedicines Water for Injection 2 ml, 5 ml, 10 mlInjectionP, S,T Section: 27 - Vitamins and Minerals Route of Administration/ Dosage Form StrengthsCategoryMedicines 100 mg, 500 mgTabletsP.S,TAscorbic Acid Calcium carbonate 250 mg, 500 mgTabietsP,S,T liiluitivitamins (As per Scheduie V of Drugs and Cosmetics Rules) TabletsP,S,T 50 mgTabletsP,S,T P,S,T Nicotinamide 25 mgTabietsPyridoxine 5 mg. TabietsP,S,TRiboflavin 100 mgTabietsP,S,TThiamine 5000lU, 50000lU,100000Tabiets CapsuiesP,S,T lU,Vitamin A 50000 lU/ml 0,25 mg, 1 mg Injection CapsuiesP.S,TVitamin D (Erqocalciferoi) Added Medicines lOOmg/ml in 10 ml ampouleCalcium gluconate InjectionP,S,T

SCHEDULE-II FORM- I APPLICATION FOR PRICE FIXATION / REVISION OF A NEW DRUG FORMULATION RELATED TO NLEM FORMULATION (See paragraphs 2(u),5,7,8,9,15) PROFORMA FOR Name of the formuiation: iVame and address of the manufacturer/importer: Name of the Marketing Company, if any: labei claimed and approved by Drug Control Authorities: Drugs Control Authority Permission Number and Date (copy to be enclosed). Date of commencement of production / import: Type of formulation (Tablets/Capsules/ Syrup/ Injection/ Ointment/ Size of packs (lO's/ lOO's/ 1 ml/ 2 ml/ 10 ml/ 5 gms/ 10 gms etc.) Therapeutic category/ use of the formulation. The Retail Price claimed for approval Reason for submission of application for price fixation / revision. Any other information relevant to product and its process l Composition as per Powder of manufacturing/

1.

2.

3.

4.

5.

6. etc.):

7. S; I

9.

10.

11. packaging/ distribution.

12. 64 — • extraordinary The informaUon furnished above is correct and true to the Place: best of my knowledg [Part II—Sec. 3fii)1 e and belief. Authorized Signatory: Name: Designation: l><^ Date: .?

SCHEDULE-II FORM - II PROFORMA FOR SUBMISSION OF revised-prices for scheduled FORMUUTIONS (See paragraph 16)

1. Name and address of the marketing company, if any.2. SI. No. Name of the Product (Formulation and its dosage forms) Composition of scheduled formulation/ new drug Pack WPI Price to retailer .. (incl. of E.D.) Maximum Retail Price (incl. of E.D:&Taxes) (Rs.) Ceiling Price (Notified) Effec-Size change w.r.t. preced ing Year tive (Rs.) Batch (Rs.) No. and date Pre- Revised Revi- Pre- Revi- Revised sed sed(1) (2) (3) (4) (5) (6) (7) (8) (9)Scheduled Formulations Own Manufactured Formulations (Id) (11) Purchased/Imported Formulations Notes;; In case of purchased formulation. The information furnished above r Place: name of the manufacturer shaii be indicated. » correa and true to the best of nty knowledge and belief. Authorised Signatory: Name: Designation: Date:

SCHEDULE-II form - III proforma for quarterly return [See paragraphs 21(1)] and sale of

1. Name and address of the

2. Name and address of i

3. Details of production/import manufacturer/importer ; marketing company, if any : and sale for the Quarter of a Year: 1 65 ma an ima : armwa[«?m ll-73Trg 3(ii)] TABLE-A Unit(No/kg/Ltr)Dosage FormComposition/Strength ,Name of the Scheduled Formulation

(4)(3)(2)(1) Production/Import Level Current Year € Previous Year TIT 3^ Quarter 4"' Quarter2^ QuartersT r' Quarter ill161 Domestic Sale Current Year 2"° Quarter~ Previous Year 4"’ Quarter3"'’ Quarter1°' Quarter 1141(13)(12)(11)IM TABLE-B Installed CapacityUnit(Kg/Ltr) Name of the Bulk Drug/API used in Scheduled Formulation

(3)(2)

(1) Production/Import Level Current Year 2”° Quarter Previous.Year r Quarter3^°. Quarter V Quarter

(8)(7)(6)(5)(4). Domestic'Sale Current Year 2”° Quarter ~ Previous Year 4'" Quarter3"* Quarter1^'Quarter

(13)(12)(11)(10)(9) belief. Authorised Signatory: Name: Designation: Place: Date: t

SCHEDULE-II FORM ■ IV proforma [See paragraphs 21(2)1

1. Name of the formulation: 66 THU GAZETTE OF INDIA : EXTRAORDINARY [Part 11—sec. 3(ii)]

2. Name and address of the manufacturer/importer;

3. Name of the Marketing Company, if any:

4. Composition as per label claimed and approved by Drug Control Authorities:

5. Drugs Control Authority Permission Number and Date (copy to be enclosed):

6. Celling Price and date of notification;

7. Existing maximum retail price (MRP) and its effective date:

8. Therapeutic category as per NLEM:

9. Date of commencement of production / import

10. Proposed date of discontinuation; V?

11. Reasons for discontinuation of production / import;

12. Year-wise Production/Import during the last 5 years including current year

13. Year-wise sale during the last 5 years including current year

15. Any other information relevant to discontinuation of scheduled formulation: Authorized Signatory: Name: Place: Date: Designation:

SCHEDULE-II FORM-V PROFORMA FOR PRICE LIST [See paragraphs 2(x),24,25,26]

1. Name and address of the manufacturer / importer / distributor

2. Name and address of the marketing company, if any. TABLE-A SI. No. Name of the Product (Formulation and its dosage forms) Composition approved by Drug Control Authorities Pack Size Price to retailer (incl. of ED.)(Rs.) Maximum Retail Price (incl. of E.D.&Taxes) (Rs.) 9

(1) (2) (3) (4) (5) (6)Scheduled Formulations Own Manufactured Formulations Purchased/Imported Formulations 67 TABLE-B Maximum Retail Price (incl. of E.D.&Taxes) (Rs.) Price to retailer (incl. of E.D.) (Rs.) Pack SizeComposition approved by Drug Control ■Authorities Name of the Product (Formulation and its dosage forms) SI. No.

(6)(5)(4)(3)(2)(1) Non-Scheduled Formulations Own Manufactured Formulations Purchased/Imported Formulations In case of purchased formulation, name of the manufacturer shall be indicated. The information furnished above is correct and true to the best of my knowledge and belief. Notes:- Authorised Signatory: Name: Designation: Place: Date: t Printed by the Manager. Government of Ind.a Ring Road, Mayjur, New Delhi-110064 and Published by the Controller of Pubheations, Delhi-110054.